Aurinia Pharmaceuticals Inc. (SEC Filing Page | XBRL Cloud Viewer | XBRL Instance)

Line Label Object Class Period Type Balance Report ElementName
1 0001000 - Document - Document and Entity Information Network

*

*

 http://www.auriniapharma.com/role/DocumentAndEntityInformation
2 Implied Table Table

*

*

 implied:Table
3 Document and Entity Information [Abstract] Abstract auph:DocumentandEntityInformationAbstract
4 Entity Registrant Name Concept (Text/String) For Period dei:EntityRegistrantName
5 Entity Central Index Key Concept (CIK Number) For Period dei:EntityCentralIndexKey
6 Document Type Concept (Submission Type) For Period dei:DocumentType
7 Amendment Flag Concept (Yes/No) For Period dei:AmendmentFlag
8 Document Period End Date Concept (Date) For Period dei:DocumentPeriodEndDate
9 Current Fiscal Year End Date Concept (Month/Day) For Period dei:CurrentFiscalYearEndDate
10 Document Fiscal Year Focus Concept (Year) For Period dei:DocumentFiscalYearFocus
11 Document Fiscal Period Focus Concept (Fiscal Period) For Period dei:DocumentFiscalPeriodFocus
12 Entity Current Reporting Status Concept (Yes/No) For Period dei:EntityCurrentReportingStatus
13 Entity Common Stock, Shares Outstanding Concept (Shares) As Of dei:EntityCommonStockSharesOutstanding
14 1001000 - Statement - Consolidated Statements of Financial Position Network

*

*

 http://www.auriniapharma.com/role/ConsolidatedStatementsOfFinancialPosition
15 Implied Table Table

*

*

 implied:Table
16 Statement of financial position [abstract] Abstract ifrs-full:StatementOfFinancialPositionAbstract
17 Assets Abstract ifrs-full:AssetsAbstract
18 Current assets Abstract ifrs-full:CurrentAssetsAbstract
19 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
20 Short term investments (note 5) Concept (Monetary) As Of Debit ifrs-full:CurrentInvestments
21 Accounts receivable and accrued interest receivable Concept (Monetary) As Of Debit ifrs-full:CurrentTradeReceivables
22 Prepaid expenses, deposits and other Concept (Monetary) As Of Debit ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
23 Current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssets
24 Clinical trial contract deposits Concept (Monetary) As Of Debit ifrs-full:LongtermDeposits
25 Property and equipment (note 6) Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
26 Acquired intellectual property and other intangible assets (note 7) Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsOtherThanGoodwill
27 Assets Concept (Monetary) As Of Debit ifrs-full:Assets
28 Liabilities Abstract ifrs-full:LiabilitiesAbstract
29 Current liabilities Abstract ifrs-full:CurrentLiabilitiesAbstract
30 Accounts payable and accrued liabilities (note 8) Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayables
31 Current portion of deferred revenue (note 9) Concept (Monetary) As Of Credit ifrs-full:DeferredIncomeClassifiedAsCurrent
32 Contingent consideration (note 10) Concept (Monetary) As Of Credit auph:Currentcontingentconsideration
33 Current liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentLiabilities
34 Deferred revenue (note 9) Concept (Monetary) As Of Credit ifrs-full:DeferredIncomeClassifiedAsNoncurrent
35 Contingent consideration (note 10) Concept (Monetary) As Of Credit auph:Noncurrentcontingentconsideration
36 Derivative warrant liabilities (notes 11 and 23) Concept (Monetary) As Of Credit ifrs-full:NoncurrentDerivativeFinancialLiabilities
37 Liabilities Concept (Monetary) As Of Credit ifrs-full:Liabilities
38 Shareholders’ Equity Abstract ifrs-full:EquityAbstract
39 Share capital Abstract auph:SharecapitalAbstract
40 Common shares (note 12) Concept (Monetary) As Of Credit ifrs-full:IssuedCapital
41 Warrants (note 12) Concept (Monetary) As Of Credit auph:Warrants
42 Contributed surplus Concept (Monetary) As Of Credit ifrs-full:CapitalReserve
43 Accumulated other comprehensive loss Concept (Monetary) As Of Credit ifrs-full:AccumulatedOtherComprehensiveIncome
44 Deficit Concept (Monetary) As Of Credit ifrs-full:RetainedEarnings
45 Equity Concept (Monetary) As Of Credit ifrs-full:Equity
46 Equity and liabilities Concept (Monetary) As Of Credit ifrs-full:EquityAndLiabilities
47 Commitments and contingencies (note 20) Concept (Monetary) As Of Credit auph:CommitmentsAndContingencies1
48 1002000 - Statement - Consolidated Statment of Operations and Comprehensive Loss Network

*

*

 http://www.auriniapharma.com/role/ConsolidatedStatmentOfOperationsAndComprehensiveLoss
49 Implied Table Table

*

*

 implied:Table
50 Profit or loss [abstract] Abstract ifrs-full:IncomeStatementAbstract
51 Revenue (note 9) Abstract ifrs-full:RevenueAbstract
52 Licensing revenue Concept (Monetary) For Period Credit ifrs-full:LicenceFeeIncome
53 Contract revenue Concept (Monetary) For Period Credit auph:Researchanddevelopmentrevenue
54 Revenue Concept (Monetary) For Period Credit ifrs-full:Revenue
55 Expenses Abstract ifrs-full:ExpenseByNatureAbstract
56 Research and development (note 13) Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
57 Corporate, administration and business development (note 13) Concept (Monetary) For Period Debit ifrs-full:GeneralAndAdministrativeExpense
58 Amortization of acquired intellectual property and other intangible assets (note 7) Concept (Monetary) For Period ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
59 Amortization of property and equipment Concept (Monetary) For Period ifrs-full:DepreciationPropertyPlantAndEquipment
60 Other expense (income) (note 14) Concept (Monetary) For Period Credit ifrs-full:OtherOperatingIncomeExpense
61 Expenses Concept (Monetary) For Period Debit ifrs-full:OperatingExpense
62 Net loss before change in estimated fair value of derivative warrant liabilities Concept (Monetary) For Period Credit ifrs-full:ProfitLossFromOperatingActivities
63 Change in estimated fair value of derivative warrant liabilities (note 11) Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
64 Loss before income taxes Concept (Monetary) For Period Credit ifrs-full:ProfitLossBeforeTax
65 Income tax expense (note 15) Concept (Monetary) For Period Debit auph:Taxexpenseincome
66 Net loss for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
67 Net change in fair value of short term investments (note 3) Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets
68 Net comprehensive loss for the year Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
69 Basic and diluted loss per common share (in dollars per share) Concept (Share) For Period ifrs-full:BasicAndDilutedEarningsLossPerShare
70 1003000 - Statement - Consolidated Statements of Changes in Shareholders' Equity Network

*

*

 http://www.auriniapharma.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity
71 Statement of changes in equity [table] Table

*

*

 ifrs-full:StatementOfChangesInEquityTable
72 Retrospective application and retrospective restatement [axis] Axis ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis
73 Currently stated [member] Member ifrs-full:RestatedMember
74 Previously stated [member] Member ifrs-full:PreviouslyStatedMember
75 Increase (decrease) due to changes in accounting policy required by IFRSs [member] Member ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember
76 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
77 Equity [member] Member ifrs-full:EquityMember
78 Common shares Member ifrs-full:IssuedCapitalMember
79 Warrants Member auph:WarrantsMember
80 Contributed surplus Member ifrs-full:SharePremiumMember
81 Deficit Member ifrs-full:RetainedEarningsMember
82 Accumulated other comprehensive loss Member ifrs-full:AccumulatedOtherComprehensiveIncomeMember
83 Statement of changes in equity [line items] LineItems ifrs-full:StatementOfChangesInEquityLineItems
84 Profit (loss) before tax Concept (Monetary) For Period Credit ifrs-full:ProfitLossBeforeTax
85 Equity, opening balance Concept (Monetary) As Of Credit ifrs-full:Equity
86 Other comprehensive income Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncome
87 Issue of common shares Concept (Monetary) For Period Credit ifrs-full:IssueOfEquity
88 Share issue costs Concept (Monetary) For Period Debit ifrs-full:ShareIssueRelatedCost
89 Exercise of warrants Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
90 Exercise of derivative warrants Concept (Monetary) For Period Credit auph:Increasedecreasethroughexerciseofderivativeliabilitywarrantsequity
91 Exercise of stock options Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
92 Stock-based compensation Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
93 Net loss for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
94 Net loss and comprehensive loss for the year Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
95 Equity, closing balance Concept (Monetary) As Of Credit ifrs-full:Equity
96 1004000 - Statement - Consolidated Statements of Cash Flows Network

*

*

 http://www.auriniapharma.com/role/ConsolidatedStatementsOfCashFlows
97 Implied Table Table

*

*

 implied:Table
98 Consolidated Statement of Cash Flows [Abstract] Abstract auph:ConsolidatedStatementofCashFlowsAbstract
99 Cash flow provided by (used in) Operating activities Abstract ifrs-full:CashFlowsFromUsedInOperatingActivitiesAbstract
100 Net loss for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
101 Adjustments for Abstract ifrs-full:AdjustmentsForReconcileProfitLossAbstract
102 Amortization of deferred revenue Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome
103 Amortization of property and equipment Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDepreciationExpense
104 Amortization of acquired intellectual property and other intangible assets Concept (Monetary) For Period Debit auph:Amortizationofacquiredintellectualpropertyandotherintangibleassets
105 Change in value and amortization of short term investments discount (premium) (note 18) Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForFairValueGainsLosses
106 Revaluation of contingent consideration Concept (Monetary) For Period Debit auph:Revaluationofcontingentconsiderations
107 Loss on disposal of equipment Concept (Monetary) For Period Credit ifrs-full:GainsOnDisposalsOfPropertyPlantAndEquipment
108 Revaluation of derivative warrant liability Concept (Monetary) For Period Credit auph:Revaluationofderivativewarrantliability
109 Change in estimated fair value of derivative warrant liabilities Concept (Monetary) For Period Credit ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives
110 Stock-based compensation Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForSharebasedPayments
111 Adjustments to reconcile profit (loss) Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForReconcileProfitLoss
112 Contingent consideration milestones paid Concept (Monetary) For Period Credit auph:Paymentofcontingentconsiderationmilestoneachievement
113 Net change in other operating assets and liabilities (note 18) Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseInWorkingCapital
114 Net cash used in operating activities Concept (Monetary) For Period ifrs-full:CashFlowsFromUsedInOperatingActivities
115 Investing activities (note 18) Abstract ifrs-full:CashFlowsFromUsedInInvestingActivitiesAbstract
116 Purchase of short term investments Concept (Monetary) For Period Credit ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities
117 Proceeds on disposal/maturity of short term investments Concept (Monetary) For Period Debit ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
118 Purchase of equipment Concept (Monetary) For Period Credit ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
119 Capitalized patent costs Concept (Monetary) For Period Credit ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
120 Net cash used in investing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInInvestingActivities
121 Proceeds from exercise of warrants Abstract ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract
122 Net proceeds from issuance of common shares Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssueOfOrdinaryShares
123 Proceeds from exercise of derivative warrants Concept (Monetary) For Period Debit auph:Proceedsfromexerciseofderivativewarrants
124 Proceeds from exercise of warrants Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssuingOtherEquityInstruments
125 Proceeds from exercise of stock options Concept (Monetary) For Period Debit ifrs-full:ProceedsFromExerciseOfOptions
126 Net cash generated from financing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInFinancingActivities
127 (Decrease) Increase in cash and cash equivalents during the year Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
128 Cash and cash equivalents – Beginning of year Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
129 Cash and cash equivalents – End of year Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
130 2101100 - Disclosure - Corporate information Network

*

*

 http://www.auriniapharma.com/role/CorporateInformation
131 Implied Table Table

*

*

 implied:Table
132 Corporate Information [Abstract] Abstract auph:CorporateInformationAbstract
133 Corporate information Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory
134 2102100 - Disclosure - Basis of preparation Network

*

*

 http://www.auriniapharma.com/role/BasisOfPreparation
135 Implied Table Table

*

*

 implied:Table
136 Basis of Preparation [Abstract] Abstract auph:BasisofPreparationAbstract
137 Basis of preparation Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
138 2103100 - Disclosure - Recent Changes in Accounting Standards Recent Changes in Accounting Standards Network

*

*

 http://www.auriniapharma.com/role/RecentChangesInAccountingStandardsRecentChangesInAccountingStandards
139 Implied Table Table

*

*

 implied:Table
140 Disclosure of changes in accounting policies, accounting estimates and errors [Abstract] Abstract auph:DisclosureofchangesinaccountingpoliciesaccountingestimatesanderrorsAbstract
141 Recent Changes in Accounting Standards Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory
142 2104100 - Disclosure - Critical accounting estimates and judgments Network

*

*

 http://www.auriniapharma.com/role/CriticalAccountingEstimatesAndJudgments
143 Implied Table Table

*

*

 implied:Table
144 Critical accounting estimates and judgements [Abstract] Abstract auph:CriticalaccountingestimatesandjudgementsAbstract
145 Critical accounting estimates and judgements Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
146 2105100 - Disclosure - Short term investments Network

*

*

 http://www.auriniapharma.com/role/ShortTermInvestments
147 Implied Table Table

*

*

 implied:Table
148 Short-term investment [Abstract] Abstract auph:ShortterminvestmentAbstract
149 Short term investments Concept (Text Block (HTML)) For Period auph:InvestmentCurrentTextBlock
150 2106100 - Disclosure - Property and equipment Network

*

*

 http://www.auriniapharma.com/role/PropertyAndEquipment
151 Implied Table Table

*

*

 implied:Table
152 Disclosure of detailed information about property, plant and equipment [abstract] Abstract ifrs-full:DisclosureOfPropertyPlantAndEquipmentAbstract
153 Property and equipment Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
154 2107100 - Disclosure - Acquired intellectual property and other intangible assets Network

*

*

 http://www.auriniapharma.com/role/AcquiredIntellectualPropertyAndOtherIntangibleAssets
155 Implied Table Table

*

*

 implied:Table
156 Acquired Intellectual Property and Other Intangible Assets [Abstract] Abstract auph:AcquiredIntellectualPropertyandOtherIntangibleAssetsAbstract
157 Acquired intellectual property and other intangible assets Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIntangibleAssetsExplanatory
158 2108100 - Disclosure - Accounts payable and accrued liabilities Network

*

*

 http://www.auriniapharma.com/role/AccountsPayableAndAccruedLiabilities
159 Implied Table Table

*

*

 implied:Table
160 Accounts payable and accrued liabilities [Abstract] Abstract auph:AccountspayableandaccruedliabilitiesAbstract
161 Accounts payable and accrued liabilities Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
162 2109100 - Disclosure - Licensing revenue and deferred revenue Network

*

*

 http://www.auriniapharma.com/role/LicensingRevenueAndDeferredRevenue
163 Implied Table Table

*

*

 implied:Table
164 Revenue and deferred revenue [Abstract] Abstract auph:RevenueanddeferredrevenueAbstract
165 Revenue and deferred revenue Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfRevenueExplanatory
166 2110100 - Disclosure - Contingent consideration Network

*

*

 http://www.auriniapharma.com/role/ContingentConsideration
167 Implied Table Table

*

*

 implied:Table
168 Contingent Consideration [Abstract] Abstract auph:ContingentConsiderationAbstract
169 Contingent consideration Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfContingentLiabilitiesExplanatory
170 2111100 - Disclosure - Derivative warrant liabilities Network

*

*

 http://www.auriniapharma.com/role/DerivativeWarrantLiabilities
171 Implied Table Table

*

*

 implied:Table
172 Derivative warrant liabilities [Abstract] Abstract auph:DerivativewarrantliabilitiesAbstract
173 Derivative warrant liabilities Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory
174 2112100 - Disclosure - Share capital Network

*

*

 http://www.auriniapharma.com/role/ShareCapital
175 Implied Table Table

*

*

 implied:Table
176 Share capital [Abstract] Abstract auph:SharecapitalAbstract
177 Share capital Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
178 2113100 - Disclosure - Nature of expenses Network

*

*

 http://www.auriniapharma.com/role/NatureOfExpenses
179 Implied Table Table

*

*

 implied:Table
180 Expenses by nature [abstract] Abstract ifrs-full:ExpenseByNatureAbstract
181 Nature of expenses Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfExpensesByNatureExplanatory
182 2114100 - Disclosure - Other expenses (income) Network

*

*

 http://www.auriniapharma.com/role/OtherExpensesIncome
183 Implied Table Table

*

*

 implied:Table
184 Other Expenses (Income) [Abstract] Abstract auph:OtherExpensesIncomeAbstract
185 Other expenses (income) Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory
186 2115100 - Disclosure - Income taxes Network

*

*

 http://www.auriniapharma.com/role/IncomeTaxes
187 Implied Table Table

*

*

 implied:Table
188 Income taxes [Abstract] Abstract auph:IncometaxesAbstract
189 Income taxes Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIncomeTaxExplanatory
190 2116100 - Disclosure - Net loss per common share Network

*

*

 http://www.auriniapharma.com/role/NetLossPerCommonShare
191 Implied Table Table

*

*

 implied:Table
192 Net loss per common share [Abstract] Abstract auph:NetlosspercommonshareAbstract
193 Net loss per common share Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEarningsPerShareExplanatory
194 2117100 - Disclosure - Segment disclosures Network

*

*

 http://www.auriniapharma.com/role/SegmentDisclosures
195 Implied Table Table

*

*

 implied:Table
196 Segment disclosures [Abstract] Abstract auph:SegmentdisclosuresAbstract
197 Segment disclosures Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory
198 2118100 - Disclosure - Supplementary cash flow information Network

*

*

 http://www.auriniapharma.com/role/SupplementaryCashFlowInformation
199 Implied Table Table

*

*

 implied:Table
200 Supplementary Cash Flow Information [Abstract] Abstract auph:SupplementaryCashFlowInformationAbstract
201 Supplementary cash flow information Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCashFlowStatementExplanatory
202 2119100 - Disclosure - Related parties Network

*

*

 http://www.auriniapharma.com/role/RelatedParties
203 Implied Table Table

*

*

 implied:Table
204 Related parties [Abstract] Abstract auph:RelatedpartiesAbstract
205 Related parties Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfRelatedPartyExplanatory
206 2120100 - Disclosure - Commitments and contingencies Network

*

*

 http://www.auriniapharma.com/role/CommitmentsAndContingencies
207 Implied Table Table

*

*

 implied:Table
208 Commitments and contingencies [Abstract] Abstract auph:CommitmentsandcontingenciesAbstract
209 Commitments and contingencies Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory
210 2121100 - Disclosure - Capital management Network

*

*

 http://www.auriniapharma.com/role/CapitalManagement
211 Implied Table Table

*

*

 implied:Table
212 Capital management [Abstract] Abstract auph:CapitalmanagementAbstract
213 Capital management Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory
214 2122100 - Disclosure - Financial instruments and fair values Network

*

*

 http://www.auriniapharma.com/role/FinancialInstrumentsAndFairValues
215 Implied Table Table

*

*

 implied:Table
216 Disclosure of detailed information about financial instruments [abstract] Abstract ifrs-full:DisclosureOfFinancialInstrumentsAbstract
217 Financial instruments and fair values Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory
218 2123100 - Disclosure - Subsequent event Network

*

*

 http://www.auriniapharma.com/role/SubsequentEvent
219 Implied Table Table

*

*

 implied:Table
220 Subsequent events [Abstract] Abstract auph:SubsequenteventsAbstract
221 Subsequent events Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
222 2202201 - Disclosure - Basis of preparation (Policies) Network

*

*

 http://www.auriniapharma.com/role/BasisOfPreparationPolicies
223 Implied Table Table

*

*

 implied:Table
224 Basis of Preparation [Abstract] Abstract auph:BasisofPreparationAbstract
225 Consolidation Concept (Text Block (HTML)) For Period auph:DescriptionofaccountingpolicyforconsolidationPolicyTextBlock
226 Translation of foreign currencies Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
227 Revenue recognition Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
228 Cash and cash equivalents Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents
229 Property and equipment Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
230 Acquired intellectual property and other than goodwill Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory
231 Impairment of non-financial assets Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory
232 Share capital Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory
233 Provisions Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory
234 Research and development expense Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
235 Stock-based compensation Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
236 Leases Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
237 Income tax Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
238 Earnings (loss) per share Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
239 Financial instruments Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory
240 Impairment of financial assets Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory
241 New standards, amendments and interpretations not yet adopted Concept (Text Block (HTML)) For Period auph:DescriptionofaccountingpolicyfornewaccountingpronouncementsPolicyTextBlock
242 2302302 - Disclosure - Basis of preparation (Tables) Network

*

*

 http://www.auriniapharma.com/role/BasisOfPreparationTables
243 Implied Table Table

*

*

 implied:Table
244 Basis of Preparation [Abstract] Abstract auph:BasisofPreparationAbstract
245 Disclosure of major categories of property and equipment amortization Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
246 2303301 - Disclosure - Recent Changes in Accounting Standards (Tables) Network

*

*

 http://www.auriniapharma.com/role/RecentChangesInAccountingStandardsTables
247 Implied Table Table

*

*

 implied:Table
248 Disclosure of changes in accounting policies, accounting estimates and errors [Abstract] Abstract auph:DisclosureofchangesinaccountingpoliciesaccountingestimatesanderrorsAbstract
249 Disclosure of initial application of standards or interpretations Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations
250 2305301 - Disclosure - Short term investments (Tables) Network

*

*

 http://www.auriniapharma.com/role/ShortTermInvestmentsTables
251 Implied Table Table

*

*

 implied:Table
252 Investments Schedule [Abstract] Abstract invest:InvestmentsScheduleAbstract
253 Investments Concept (Text Block (HTML)) For Period invest:InvestmentTableTextBlock
254 2306301 - Disclosure - Property and equipment (Tables) Network

*

*

 http://www.auriniapharma.com/role/PropertyAndEquipmentTables
255 Implied Table Table

*

*

 implied:Table
256 Disclosure of detailed information about property, plant and equipment [abstract] Abstract ifrs-full:DisclosureOfPropertyPlantAndEquipmentAbstract
257 Disclosure of property, plant and equipment Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
258 2307301 - Disclosure - Acquired intellectual property and other intangible assets (Tables) Network

*

*

 http://www.auriniapharma.com/role/AcquiredIntellectualPropertyAndOtherIntangibleAssetsTables
259 Implied Table Table

*

*

 implied:Table
260 Acquired Intellectual Property and Other Intangible Assets [Abstract] Abstract auph:AcquiredIntellectualPropertyandOtherIntangibleAssetsAbstract
261 Disclosure of detailed information about intangible assets Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory
262 2308301 - Disclosure - Accounts payable and accrued liabilities (Tables) Network

*

*

 http://www.auriniapharma.com/role/AccountsPayableAndAccruedLiabilitiesTables
263 Implied Table Table

*

*

 implied:Table
264 Accounts payable and accrued liabilities [Abstract] Abstract auph:AccountspayableandaccruedliabilitiesAbstract
265 Disclosure of trade and other payables Concept (Text Block (HTML)) For Period auph:DisclosureoftradeandotherpayablesTableTextBlock
266 2310301 - Disclosure - Contingent consideration (Tables) Network

*

*

 http://www.auriniapharma.com/role/ContingentConsiderationTables
267 Implied Table Table

*

*

 implied:Table
268 Contingent Consideration [Abstract] Abstract auph:ContingentConsiderationAbstract
269 Disclosure of contingent liabilities Concept (Text Block (HTML)) For Period auph:DisclosureofcontingentliabilitiesTableTextBlock
270 2311301 - Disclosure - Derivative warrant liabilities (Tables) Network

*

*

 http://www.auriniapharma.com/role/DerivativeWarrantLiabilitiesTables
271 Implied Table Table

*

*

 implied:Table
272 Derivative warrant liabilities [Abstract] Abstract auph:DerivativewarrantliabilitiesAbstract
273 Disclosure of derivative warrant liabilities Concept (Text Block (HTML)) For Period auph:DisclosureofderivativewarrantliabilitiesTableTextBlock
274 Disclosure of the estimated fair value of the derivative warrant liability Concept (Text Block (HTML)) For Period auph:DisclosureoftheestimatedfairvalueofthederivativewarrantliabilityTableTextBlock
275 2312301 - Disclosure - Share capital (Tables) Network

*

*

 http://www.auriniapharma.com/role/ShareCapitalTables
276 Implied Table Table

*

*

 implied:Table
277 Share capital [Abstract] Abstract auph:SharecapitalAbstract
278 Disclosure of classes of share capital Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
279 Disclosure of warrants issued Concept (Text Block (HTML)) For Period auph:DisclosureofwarrantsissuedTableTextBlock
280 Disclosure of outstanding warrants Concept (Text Block (HTML)) For Period auph:DisclosureofoutstandingwarrantsTableTextBlock
281 Disclosure of number and weighted average exercise prices of share options Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
282 Disclosure of stock options granted Concept (Text Block (HTML)) For Period auph:DisclosureofstockoptionsgrantedTableTextBlock
283 Disclosure of weighted average assumptions used to estimate fair values of options granted Concept (Text Block (HTML)) For Period auph:DisclosureofweightedaverageassumptionsusedtoestimatefairvaluesofoptionsgrantedTableTextBlock
284 Disclosure of number and weighted average remaining contractual life of outstanding share options Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
285 2313301 - Disclosure - Nature of expenses (Tables) Network

*

*

 http://www.auriniapharma.com/role/NatureOfExpensesTables
286 Implied Table Table

*

*

 implied:Table
287 Expenses by nature [abstract] Abstract ifrs-full:ExpenseByNatureAbstract
288 Disclosure of research and development Concept (Text Block (HTML)) For Period auph:ResearchanddevelopmentTableTextBlock
289 Disclosure of administrative expenses Concept (Text Block (HTML)) For Period auph:AdministrativeexpensesTableTextBlock
290 2314301 - Disclosure - Other expenses (income) (Tables) Network

*

*

 http://www.auriniapharma.com/role/OtherExpensesIncomeTables
291 Implied Table Table

*

*

 implied:Table
292 Other Expenses (Income) [Abstract] Abstract auph:OtherExpensesIncomeAbstract
293 Other expense (income) Concept (Text Block (HTML)) For Period auph:OtherexpenseincomeTableTextBlock
294 2315301 - Disclosure - Income taxes (Tables) Network

*

*

 http://www.auriniapharma.com/role/IncomeTaxesTables
295 Implied Table Table

*

*

 implied:Table
296 Income taxes [Abstract] Abstract auph:IncometaxesAbstract
297 Schedule for Expiration of Income Tax Losses and Credits Concept (Text Block (HTML)) For Period auph:IncometaxesexpirationoflossesandcreditsTableTextBlock
298 Schedule of Deferred Income Tax Assets Concept (Text Block (HTML)) For Period auph:DeferredtaxassetsliabilitiesTableTextBlock
299 Schedule of Income Tax Recovery Concept (Text Block (HTML)) For Period auph:IncometaxratereconciliationTableTextBlock
300 2316301 - Disclosure - Net loss per common share (Tables) Network

*

*

 http://www.auriniapharma.com/role/NetLossPerCommonShareTables
301 Implied Table Table

*

*

 implied:Table
302 Net loss per common share [Abstract] Abstract auph:NetlosspercommonshareAbstract
303 Disclosure of net loss per common share Concept (Text Block (HTML)) For Period ifrs-full:EarningsPerShareExplanatory
304 Disclosure of anti-dilutive securities excluded from computation of EPS Concept (Text Block (HTML)) For Period auph:AntidilutivesecuritiesexcludedfromcomputationofearningspershareTableTextBlock
305 2317301 - Disclosure - Segment disclosures (Tables) Network

*

*

 http://www.auriniapharma.com/role/SegmentDisclosuresTables
306 Implied Table Table

*

*

 implied:Table
307 Segment disclosures [Abstract] Abstract auph:SegmentdisclosuresAbstract
308 Disclosure of segment geographic information Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfOperatingSegmentsExplanatory
309 2318301 - Disclosure - Supplementary cash flow information (Tables) Network

*

*

 http://www.auriniapharma.com/role/SupplementaryCashFlowInformationTables
310 Implied Table Table

*

*

 implied:Table
311 Supplementary Cash Flow Information [Abstract] Abstract auph:SupplementaryCashFlowInformationAbstract
312 Disclosure of change in other assets and liabilities Concept (Text Block (HTML)) For Period auph:DisclosureofchangeinotherassetsandliabilitiesTableTextBlock
313 Disclosure of change in financing and investing activities Concept (Text Block (HTML)) For Period auph:DisclosureofchangeinfinancingandinvestingactivitiesTableTextBlock
314 2319301 - Disclosure - Related parties (Tables) Network

*

*

 http://www.auriniapharma.com/role/RelatedPartiesTables
315 Implied Table Table

*

*

 implied:Table
316 Related parties [Abstract] Abstract auph:RelatedpartiesAbstract
317 Disclosure of transactions between related parties Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
318 2320301 - Disclosure - Commitments and contingencies (Tables) Network

*

*

 http://www.auriniapharma.com/role/CommitmentsAndContingenciesTables
319 Implied Table Table

*

*

 implied:Table
320 Commitments and contingencies [Abstract] Abstract auph:CommitmentsandcontingenciesAbstract
321 Disclosure of future minimum lease payments Concept (Text Block (HTML)) For Period auph:DisclosureofCommitmentsbyCommitmentTableTextBlock
322 2322301 - Disclosure - Financial instruments and fair values (Tables) Network

*

*

 http://www.auriniapharma.com/role/FinancialInstrumentsAndFairValuesTables
323 Implied Table Table

*

*

 implied:Table
324 Disclosure of detailed information about financial instruments [abstract] Abstract ifrs-full:DisclosureOfFinancialInstrumentsAbstract
325 Disclosure of foreign currencies Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCreditRiskExposureExplanatory
326 2402403 - Disclosure - Basis of preparation - Major Categories of Property and Equipment (Details) Network

*

*

 http://www.auriniapharma.com/role/BasisOfPreparationMajorCategoriesOfPropertyAndEquipmentDetails
327 Disclosure of detailed information about property, plant and equipment [table] Table

*

*

 ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable
328 Classes of intangible assets and goodwill [axis] Axis ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis
329 Intangible assets and goodwill Member ifrs-full:IntangibleAssetsAndGoodwillMember
330 Purchased intellectual property and reacquired rights Member ifrs-full:OtherIntangibleAssetsMember
331 Range [axis] Axis ifrs-full:RangeAxis
332 Ranges [member] Member ifrs-full:RangesMember
333 Bottom of range Member ifrs-full:BottomOfRangeMember
334 Top of range Member ifrs-full:TopOfRangeMember
335 Classes of property, plant and equipment [axis] Axis ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis
336 Property, plant and equipment Member ifrs-full:PropertyPlantAndEquipmentMember
337 Computer equipment and software Member auph:ComputerequipmentandsoftwareMember
338 Office equipment and furniture Member auph:OfficeequipmentandfurnitureMember
339 Disclosure of detailed information about property, plant and equipment [line items] LineItems ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems
340 Property and equipment, useful lives Concept (xbrli:durationItemType) For Period auph:Propertyplantandequipmentestimatedusefullives1
341 Acquired finite-lived intangible assets, weighted average useful life Concept (xbrli:durationItemType) For Period auph:Acquiredfinitelivedintangibleassetsweightedaverageusefullife
342 2403402 - Disclosure - Recent Changes in Accounting Standards (Details) Network

*

*

 http://www.auriniapharma.com/role/RecentChangesInAccountingStandardsDetails
343 Disclosure of changes in accounting estimates [table] Table

*

*

 ifrs-full:DisclosureOfChangesInAccountingEstimatesTable
344 Accounting estimates [axis] Axis ifrs-full:AccountingEstimatesAxis
345 Accounting estimates [member] Member ifrs-full:AccountingEstimatesMember
346 Current Investments Member auph:CurrentInvestmentsMember
347 Accumulated other comprehensive loss Member ifrs-full:AccumulatedOtherComprehensiveIncomeMember
348 New IFRSs [axis] Axis ifrs-full:NewIFRSsAxis
349 New IFRSs [member] Member ifrs-full:NewIFRSsMember
350 In accordance with IFRS 9 Member ifrs-full:InAccordanceWithIFRS9Member
351 In accordance with IFRS 16 Member ifrs-full:AtCostOrInAccordanceWithIFRS16WithinFairValueModelMember
352 Initially applied IFRSs [axis] Axis ifrs-full:InitiallyAppliedIFRSsAxis
353 Initially applied IFRSs [member] Member ifrs-full:InitiallyAppliedIFRSsMember
354 International Accounting Standards 39 Member auph:InternationalAccountingStandards39Member
355 Disclosure of changes in accounting estimates [line items] LineItems ifrs-full:DisclosureOfChangesInAccountingEstimatesLineItems
356 Short term investments (note 5) Concept (Monetary) As Of Debit ifrs-full:CurrentInvestments
357 Increase (decrease) in accounting estimate Concept (Monetary) For Period ifrs-full:IncreaseDecreaseInAccountingEstimate
358 Weighted average term of lessee's lease liabilities recognised at date of initial application of IFRS 16 Concept (xbrli:durationItemType) For Period auph:WeightedaveragetermoflesseesleaseliabilitiesrecognisedatdateofinitialapplicationofIFRS16
359 Accumulated other comprehensive loss Concept (Monetary) As Of Credit ifrs-full:AccumulatedOtherComprehensiveIncome
360 Number of non-cancelable leases Concept (Integer) As Of auph:Numberofnoncancelableleases
361 Minimum lease payments payable under non-cancellable operating lease Concept (Monetary) As Of Credit ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease
362 2405402 - Disclosure - Short term investments - (Details) Network

*

*

 http://www.auriniapharma.com/role/ShortTermInvestmentsDetails
363 Investment [Table] Table

*

*

 invest:InvestmentTable
364 Investment Issuer [Axis] Axis invest:InvestmentIssuerAxis
365 Investment Issuer [Domain] Member invest:InvestmentIssuerDomain
366 Canadian Imperial Bank of Commerce Member auph:CanadianImperialBankofCommerceMember
367 Royal Bank of Canada Member auph:RoyalBankofCanadaMember
368 Range [axis] Axis ifrs-full:RangeAxis
369 Ranges [member] Member ifrs-full:RangesMember
370 Weighted average Member ifrs-full:WeightedAverageMember
371 Investment [Line Items] LineItems invest:InvestmentLineItems
372 Financial assets at fair value Concept (Monetary) As Of Debit ifrs-full:FinancialAssetsAtFairValue
373 Financial assets at amortised cost Concept (Monetary) As Of Debit ifrs-full:FinancialAssetsAtAmortisedCost
374 Short term investments (note 5) Concept (Monetary) As Of Debit ifrs-full:CurrentInvestments
375 Investments, average term of contract Concept (Decimal) For Period auph:Investmentsaveragetermofcontract
376 Investment interest rate Concept (Pure) For Period invest:InvestmentInterestRate
377 2406402 - Disclosure - Property and equipment - Property, Plant and Equipment Rollforward (Details) Network

*

*

 http://www.auriniapharma.com/role/PropertyAndEquipmentPropertyPlantAndEquipmentRollforwardDetails
378 Disclosure of detailed information about intangible assets [table] Table

*

*

 ifrs-full:DisclosureOfIntangibleAssetsTable
379 Classes of property, plant and equipment [axis] Axis ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis
380 Property, plant and equipment Member ifrs-full:PropertyPlantAndEquipmentMember
381 Computer equipment and software Member auph:ComputerequipmentandsoftwareMember
382 Office equipment and furniture Member ifrs-full:OfficeEquipmentMember
383 Leasehold improvements Member ifrs-full:LeaseholdImprovementsMember
384 Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Axis ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
385 Carrying amount [member] Member ifrs-full:CarryingAmountMember
386 Cost Member ifrs-full:GrossCarryingAmountMember
387 Accumulated amortization Member ifrs-full:AccumulatedDepreciationAndAmortisationMember
388 Disclosure of detailed information about intangible assets [line items] LineItems ifrs-full:DisclosureOfIntangibleAssetsLineItems
389 Changes in property, plant and equipment [abstract] Abstract ifrs-full:ChangesInPropertyPlantAndEquipmentAbstract
390 As of beginning of period Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
391 Additions Concept (Monetary) For Period Debit ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
392 Disposal Concept (Monetary) For Period Credit ifrs-full:DisposalsPropertyPlantAndEquipment
393 Amortization Concept (Monetary) For Period ifrs-full:DepreciationPropertyPlantAndEquipment
394 Net book value Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
395 2407402 - Disclosure - Acquired intellectual property and other intangible assets - (Details) Network

*

*

 http://www.auriniapharma.com/role/AcquiredIntellectualPropertyAndOtherIntangibleAssetsDetails
396 Disclosure of detailed information about intangible assets [table] Table

*

*

 ifrs-full:DisclosureOfIntangibleAssetsTable
397 Classes of intangible assets other than goodwill [axis] Axis ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis
398 Intangible assets other than goodwill Member ifrs-full:IntangibleAssetsOtherThanGoodwillMember
399 Patents Member ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember
400 Acquired intellectual property and reacquired rights Member auph:AcquiredintellectualpropertyandreacquiredrightsMember
401 Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Axis ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
402 Carrying amount [member] Member ifrs-full:CarryingAmountMember
403 Cost Member ifrs-full:GrossCarryingAmountMember
404 Accumulated impairment Member ifrs-full:AccumulatedImpairmentMember
405 Disclosure of detailed information about intangible assets [line items] LineItems ifrs-full:DisclosureOfIntangibleAssetsLineItems
406 Changes in intangible assets other than goodwill [abstract] Abstract ifrs-full:ChangesInIntangibleAssetsOtherThanGoodwillAbstract
407 Opening net book value Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsOtherThanGoodwill
408 Additions Concept (Monetary) For Period Debit ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
409 Amortization for the year Concept (Monetary) For Period ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
410 Closing net book value Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsOtherThanGoodwill
411 Estimated useful lives or amortisation rates, intangible assets other than goodwill Concept (Decimal) For Period auph:Estimatedusefullivesoramortisationratesintangibleassetsotherthangoodwill
412 2408402 - Disclosure - Accounts payable and accrued liabilities - (Details) Network

*

*

 http://www.auriniapharma.com/role/AccountsPayableAndAccruedLiabilitiesDetails
413 Implied Table Table

*

*

 implied:Table
414 Accounts payable and accrued liabilities [Abstract] Abstract auph:AccountspayableandaccruedliabilitiesAbstract
415 Trade payables Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
416 Other accrued liabilities Concept (Monetary) As Of Credit ifrs-full:AccrualsClassifiedAsCurrent
417 Employee accruals Concept (Monetary) As Of Credit ifrs-full:ShorttermEmployeeBenefitsAccruals
418 Trade and other current payables Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayables
419 2409401 - Disclosure - Licensing revenue and deferred revenue (Details) Network

*

*

 http://www.auriniapharma.com/role/LicensingRevenueAndDeferredRevenueDetails
420 Disclosure of joint ventures [table] Table

*

*

 ifrs-full:DisclosureOfJointVenturesTable
421 Counterparties [axis] Axis ifrs-full:CounterpartiesAxis
422 Counterparties [member] Member ifrs-full:CounterpartiesMember
423 Contravir Pharmaceuticals, Inc. [Member] Member auph:ContravirPharmaceuticalsInc.Member
424 MAH [Member] Member auph:MerckAnimalHospitalMember
425 3SBio [Member] Member auph:A3SBioMember
426 Products and services [axis] Axis ifrs-full:ProductsAndServicesAxis
427 Products and services [member] Member ifrs-full:ProductsAndServicesMember
428 VOS [Member] Member auph:NanomicellarVoclosporinOpthalmicSolutionMember
429 Disclosure of joint ventures [line items] LineItems ifrs-full:DisclosureOfJointVenturesLineItems
430 Licensing revenue Concept (Monetary) For Period Credit ifrs-full:LicenceFeeIncome
431 Licence fee income Concept (Monetary) As Of Credit ifrs-full:DeferredIncome
432 Revenue from contracts with customers Concept (Monetary) For Period Credit ifrs-full:RevenueFromContractsWithCustomers
433 Current portion of deferred revenue (note 9) Concept (Monetary) As Of Credit ifrs-full:DeferredIncomeClassifiedAsCurrent
434 Deferred revenue (note 9) Concept (Monetary) As Of Credit ifrs-full:DeferredIncomeClassifiedAsNoncurrent
435 2410402 - Disclosure - Contingent consideration - Milestone Payments (Details) Network

*

*

 http://www.auriniapharma.com/role/ContingentConsiderationMilestonePaymentsDetails
436 Disclosure of transactions between related parties [table] Table

*

*

 ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesTable
437 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
438 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
439 Joint ventures where entity is venturer Member ifrs-full:JointVenturesWhereEntityIsVenturerMember
440 Disclosure of transactions between related parties [line items] LineItems ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesLineItems
441 2019 Concept (Monetary) For Period Credit auph:Contingentconsiderationpaymentsdueinnexttwelvemonths
442 2020 Concept (Monetary) For Period Credit auph:Contingentconsiderationpaymentsdueinsecondyear
443 2021 Concept (Monetary) For Period Credit auph:Contingentconsiderationpaymentsdueinthirdyear
444 Commitments made by entity, related party transactions Concept (Monetary) For Period ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions
445 2410403 - Disclosure - Contingent consideration - Narrative (Details) Network

*

*

 http://www.auriniapharma.com/role/ContingentConsiderationNarrativeDetails
446 Disclosure of contingent liabilities [table] Table

*

*

 ifrs-full:DisclosureOfContingentLiabilitiesTable
447 Valuation techniques used in fair value measurement [axis] Axis ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis
448 Valuation techniques [member] Member ifrs-full:ValuationTechniquesMember
449 Income approach Member ifrs-full:IncomeApproachMember
450 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
451 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
452 Joint ventures where entity is venturer Member ifrs-full:JointVenturesWhereEntityIsVenturerMember
453 Levels of fair value hierarchy [axis] Axis ifrs-full:LevelsOfFairValueHierarchyAxis
454 All levels of fair value hierarchy [member] Member ifrs-full:AllLevelsOfFairValueHierarchyMember
455 Level 3 of fair value hierarchy Member ifrs-full:Level3OfFairValueHierarchyMember
456 Range [axis] Axis ifrs-full:RangeAxis
457 Ranges [member] Member ifrs-full:RangesMember
458 Bottom of range Member ifrs-full:BottomOfRangeMember
459 Top of range Member ifrs-full:TopOfRangeMember
460 Disclosure of contingent liabilities [line items] LineItems ifrs-full:DisclosureOfContingentLiabilitiesLineItems
461 Amount of contingent consideration Concept (Monetary) As Of Credit auph:ContingentConsiderationMaximumAmount
462 Payment for contingent consideration liability Concept (Monetary) For Period Credit auph:Paymentforcontingentconsiderationliability
463 Number of milestones achieved Concept (Integer) For Period auph:Numberofmilestonesachieved
464 Discount rate used in estimate in the value of contingent consideration Concept (Percent) As Of auph:Discountrateusedinestimateinthevalueofcontingentconsideration
465 Probability of the success of milestone achievement Concept (Percent) For Period auph:Contingentconsiderationmilestoneachievementprobabilityofsuccesspercent
466 Fair value of contingent consideration Concept (Monetary) As Of Credit auph:Contingentconsiderationfairvalue
467 Revaluation of contingent consideration Concept (Monetary) For Period Debit auph:Revaluationofcontingentconsiderations
468 Effect of 10% increase in probability of success Concept (Monetary) For Period Credit auph:Contingentconsiderationeffectoftenpercentagepointincreaseinprobabilityofsuccess
469 Effect of 10% decrease in probability of success Concept (Monetary) For Period Credit auph:Contingentconsiderationeffectoftenpercentagepointdecreaseinprobabilityofsuccess
470 Effect of 12% increase in discount rate Concept (Monetary) For Period Credit auph:Contingentconsiderationeffectoftwelvepercentincreaseindiscountrate
471 Effect of 8% decrease in discount rate Concept (Monetary) For Period Credit auph:Contingentconsiderationeffectofeightpercentdecreaseindiscountrate
472 2411402 - Disclosure - Derivative warrant liabilities - Summary of derivative warrant liabilities (Details) Network

*

*

 http://www.auriniapharma.com/role/DerivativeWarrantLiabilitiesSummaryOfDerivativeWarrantLiabilitiesDetails
473 Disclosure of classes of share capital [table] Table

*

*

 ifrs-full:DisclosureOfClassesOfShareCapitalTable
474 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
475 Equity [member] Member ifrs-full:EquityMember
476 Warrants Member auph:WarrantsMember
477 Sale of Ordinary Shares, by Type [Axis] Axis auph:SaleofOrdinarySharesbyTypeAxis
478 Sale of Ordinary Shares, by Type [Domain] Member auph:SaleofOrdinarySharesbyTypeDomain
479 Bought Deal Public Offering Member auph:BoughtDealPublicOfferingMember
480 February 14, 2014 Warrants Member auph:PrivatePlacementOfferingFeb142014Member
481 Disclosure of classes of share capital [line items] LineItems ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
482 Changes in derivative financial liabilities [Roll Forward] Abstract auph:ChangesinderivativefinancialliabilitiesRollForward
483 Beginning balance of derivative financial liabilities Concept (Monetary) As Of Credit ifrs-full:NoncurrentDerivativeFinancialLiabilities
484 Conversion to equity (common shares) upon exercise of warrants Concept (Monetary) For Period Credit auph:Numberofwarrantsissuedduringperiodvalue
485 Revaluation of derivative warrant liability upon exercise of warrants Concept (Monetary) For Period Debit auph:Revaluationofderivativewarrantliabilityuponexerciseofwarrants
486 Revaluation of derivative warrant liability Concept (Monetary) For Period Credit auph:Revaluationofderivativewarrantliability
487 Ending balance of derivative financial liabilities Concept (Monetary) As Of Credit ifrs-full:NoncurrentDerivativeFinancialLiabilities
488 Changes in warrants [Roll Forward] Abstract auph:ChangesinwarrantsRollForward
489 Beginning balance of warrants outstanding (in shares) Concept (Shares) As Of auph:Numberofwarrantsoutstanding
490 Conversion to equity (common shares) upon exercise of warrants (in shares) Concept (Shares) For Period auph:Conversiontoequityconversionofwarrantsuponexercise
491 Ending balance of warrants outstanding (in shares) Concept (Shares) As Of auph:Numberofwarrantsoutstanding
492 2411403 - Disclosure - Derivative warrant liabilities - Bought deal narrative (Details) Network

*

*

 http://www.auriniapharma.com/role/DerivativeWarrantLiabilitiesBoughtDealNarrativeDetails
493 Disclosure of classes of share capital [table] Table

*

*

 ifrs-full:DisclosureOfClassesOfShareCapitalTable
494 Income Statement Location [Axis] Axis auph:IncomeStatementLocation1Axis
495 Income Statement Location [Domain] Member auph:IncomeStatementLocation1Domain
496 Other income (expense) Member auph:OtherIncomeExpenseMember
497 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
498 Equity [member] Member ifrs-full:EquityMember
499 Common shares Member ifrs-full:IssuedCapitalMember
500 Warrants Member auph:WarrantsMember
501 Classes of ordinary shares [axis] Axis ifrs-full:ClassesOfOrdinarySharesAxis
502 Ordinary shares [member] Member ifrs-full:OrdinarySharesMember
503 Common units Member auph:CommonunitsMember
504 Sale of Ordinary Shares, by Type [Axis] Axis auph:SaleofOrdinarySharesbyTypeAxis
505 Sale of Ordinary Shares, by Type [Domain] Member auph:SaleofOrdinarySharesbyTypeDomain
506 Bought Deal Public Offering Member auph:BoughtDealPublicOfferingMember
507 Disclosure of classes of share capital [line items] LineItems ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
508 Net proceeds from issuance of common shares Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssueOfOrdinaryShares
509 Number of units issued Concept (Shares) For Period auph:Numberofunitsissued
510 Share issuance, price per share (in dollars per share) Concept (Share) For Period auph:Shareissuancepricepershare
511 Private placement, number of shares per Unit Concept (Shares) For Period auph:PrivateplacementnumberofsharesperUnit
512 Warrant exercise period Concept (xbrli:durationItemType) For Period auph:Classofwarrantorrightexerciseperiod
513 Exercise price, price per unit (in dollars per share) Concept (Monetary) For Period Credit auph:Exercisepricesharepurchasewarrant
514 Derivative warrant liabilities Concept (Monetary) As Of Credit auph:Derivativewarrantliabilities
515 Share issue related cost Concept (Monetary) For Period Debit auph:ShareIssueCostsCommissionProfessionalFees
516 Number of warrants exercised Concept (Shares) For Period auph:Numberofwarrantsexercised
517 Proceeds from exercise of derivative warrants Concept (Monetary) For Period Debit auph:Proceedsfromexerciseofderivativewarrants
518 Fair value of warrants on exercise dates Concept (Monetary) As Of Credit auph:Fairvalueofwarrantsonexercisedates
519 Increase (decrease) through exercise of share purchase warrants Concept (Monetary) For Period Credit auph:Increasedecreasethroughexerciseofsharepurchasewarrants
520 Gains (losses) recognised in profit or loss, fair value measurement, liabilities Concept (Monetary) For Period ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities
521 Derivative warrant liabilities (note 10) Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilitiesAtFairValue
522 Revaluation of derivative warrant liability Concept (Monetary) For Period Credit auph:Revaluationofderivativewarrantliability
523 Revaluation of derivative warrant liability Concept (Monetary) For Period ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementLiabilities
524 2411404 - Disclosure - Derivative warrant liabilities - Assumptions used to estimate fair value of derivative warrant liability (Details) Network

*

*

 http://www.auriniapharma.com/role/DerivativeWarrantLiabilitiesAssumptionsUsedToEstimateFairValueOfDerivativeWarrantLiabilityDetails
525 Disclosure of classes of share capital [table] Table

*

*

 ifrs-full:DisclosureOfClassesOfShareCapitalTable
526 Sale of Ordinary Shares, by Type [Axis] Axis auph:SaleofOrdinarySharesbyTypeAxis
527 Sale of Ordinary Shares, by Type [Domain] Member auph:SaleofOrdinarySharesbyTypeDomain
528 February 14, 2014 Warrants Member auph:PrivatePlacementOfferingFeb142014Member
529 Bought Deal Public Offering Member auph:BoughtDealPublicOfferingMember
530 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
531 Equity [member] Member ifrs-full:EquityMember
532 Warrants Member auph:WarrantsMember
533 Disclosure of classes of share capital [line items] LineItems ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
534 Annualized volatility Concept (Percent) For Period ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
535 Risk-free interest rate Concept (Percent) For Period ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
536 Life of warrants in years Concept (Decimal) For Period ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
537 Expected dividend as percentage, warrants options granted Concept (Percent) For Period ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
538 Market price (in dollars per share) Concept (Monetary) For Period Credit auph:Marketpriceondateofissuesharewarrants
539 Fair value per Warrant (in dollars per share) Concept (Share) For Period auph:Sharewarrantsfairvalue
540 2411405 - Disclosure - Derivative warrant liabilities - Private placement offering narrative (Details) Network

*

*

 http://www.auriniapharma.com/role/DerivativeWarrantLiabilitiesPrivatePlacementOfferingNarrativeDetails
541 Disclosure of classes of share capital [table] Table

*

*

 ifrs-full:DisclosureOfClassesOfShareCapitalTable
542 Range [axis] Axis ifrs-full:RangeAxis
543 Ranges [member] Member ifrs-full:RangesMember
544 Top of range Member ifrs-full:TopOfRangeMember
545 Bottom of range Member ifrs-full:BottomOfRangeMember
546 Classes of ordinary shares [axis] Axis ifrs-full:ClassesOfOrdinarySharesAxis
547 Ordinary shares [member] Member ifrs-full:OrdinarySharesMember
548 Common units Member auph:CommonunitsMember
549 Levels of fair value hierarchy [axis] Axis ifrs-full:LevelsOfFairValueHierarchyAxis
550 All levels of fair value hierarchy [member] Member ifrs-full:AllLevelsOfFairValueHierarchyMember
551 Level 3 of fair value hierarchy Member ifrs-full:Level3OfFairValueHierarchyMember
552 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
553 Equity [member] Member ifrs-full:EquityMember
554 Warrants Member auph:WarrantsMember
555 Common shares Member ifrs-full:IssuedCapitalMember
556 Sale of Ordinary Shares, by Type [Axis] Axis auph:SaleofOrdinarySharesbyTypeAxis
557 Sale of Ordinary Shares, by Type [Domain] Member auph:SaleofOrdinarySharesbyTypeDomain
558 Private Placement Offering Feb 14 2014 Member auph:PrivatePlacementOfferingFeb142014Member
559 Disclosure of classes of share capital [line items] LineItems ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
560 Increase (decrease) through exercise of share purchase warrants Concept (Monetary) For Period Credit auph:Increasedecreasethroughexerciseofsharepurchasewarrants
561 Gains (losses) recognised in profit or loss, fair value measurement, liabilities Concept (Monetary) For Period ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities
562 Derivative warrant liabilities (note 10) Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilitiesAtFairValue
563 Net proceeds from issuance of common shares Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssueOfOrdinaryShares
564 Number of units issued Concept (Shares) For Period auph:Numberofunitsissued
565 Share issuance, price per share (in dollars per share) Concept (Share) For Period auph:Shareissuancepricepershare
566 Private placement, number of shares per Unit Concept (Shares) For Period auph:PrivateplacementnumberofsharesperUnit
567 Warrant exercise period Concept (xbrli:durationItemType) For Period auph:Classofwarrantorrightexerciseperiod
568 Exercise price, price per unit (in dollars per share) Concept (Monetary) For Period Credit auph:Exercisepricesharepurchasewarrant
569 Issued pursuant to exercise of warrants (in shares) Concept (Shares) For Period auph:Numberofsharesissuedwarrantsexercised
570 Number of cashless warrants exercised (in shares) Concept (Shares) For Period auph:Numberofwarrantsexercisedcashless
571 Fair value of warrants on exercise dates Concept (Monetary) As Of Credit auph:Fairvalueofwarrantsonexercisedates
572 Revaluation of derivative warrant liability upon exercise of warrants Concept (Monetary) For Period Debit auph:Revaluationofderivativewarrantliabilityuponexerciseofwarrants
573 Number of warrants exercised Concept (Shares) For Period auph:Numberofwarrantsexercised
574 Proceeds from exercise of derivative warrants Concept (Monetary) For Period Debit auph:Proceedsfromexerciseofderivativewarrants
575 Derivative warrant liabilities (notes 11 and 23) Concept (Monetary) As Of Credit ifrs-full:NoncurrentDerivativeFinancialLiabilities
576 Revaluation of derivative warrant liability Concept (Monetary) For Period ifrs-full:GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementLiabilities
577 Change in risk variable Concept (Percent) As Of auph:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent
578 Information about how expected ten percent increase in market price would increase fair value of derivative warrant liability Concept (Monetary) As Of Credit auph:Sensitivityanalysisfortypesofmarketriskeffectwouldincreasefairvalueofderivativewarrantliability
579 Information about how expected ten percent decrease in market price would decrease fair value of derivative warrant liability Concept (Monetary) As Of Debit auph:Sensitivityanalysisfortypesofmarketriskeffectwoulddecreasefairvalueofderivativewarrantliability
580 Change in risk variable Concept (Percent) As Of auph:SensitivityAnalysisForTypesOfVolatilityRiskReasonablyPossibleChangeInRiskVariablePercent
581 Information about how expected ten percent increase in volatility would increase fair value of derivative warrant liability Concept (Monetary) As Of Credit auph:Sensitivityanalysisfortypesofvolatilityriskwouldincreasefairvalueofderivativewarrantliability
582 Information about how expected ten percent decrease in volatility would decrease fair value of derivative warrant liability Concept (Monetary) As Of Debit auph:Sensitivityanalysisfortypesofvolatilityriskwoulddecreasefairvalueofderivativewarrantliability
583 2412402 - Disclosure - Share capital - Disclosure of shares issued (Details) Network

*

*

 http://www.auriniapharma.com/role/ShareCapitalDisclosureOfSharesIssuedDetails
584 Disclosure of classes of share capital [table] Table

*

*

 ifrs-full:DisclosureOfClassesOfShareCapitalTable
585 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
586 Equity [member] Member ifrs-full:EquityMember
587 Common shares Member ifrs-full:IssuedCapitalMember
588 Sale of Ordinary Shares, by Type [Axis] Axis auph:SaleofOrdinarySharesbyTypeAxis
589 Sale of Ordinary Shares, by Type [Domain] Member auph:SaleofOrdinarySharesbyTypeDomain
590 Public Offering Member auph:PublicofferingMember
591 Disclosure of classes of share capital [line items] LineItems ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
592 Reconciliation of number of shares issued [Abstract] Abstract auph:ReconciliationofnumberofsharesissuedAbstract
593 Number of shares issued, opening balance (in shares) Concept (Shares) As Of ifrs-full:NumberOfSharesIssued
594 Number of shares issued during period (in shares) Concept (Shares) For Period auph:Numberofsharesissuedduringperiod
595 Issued pursuant to exercise of warrants (in shares) Concept (Shares) For Period auph:Numberofsharesissuedwarrantsexercised
596 Issued pursuant to exercise of derivative liability warrants (note 10) (in shares) Concept (Shares) For Period auph:Numberofsharesissuedderivativeliabilitywarrantsexercised
597 Issued pursuant to exercise of stock options (in shares) Concept (Shares) For Period auph:Numberofsharesissuedoptionsexercised
598 Number of shares issued, closing balance (in shares) Concept (Shares) As Of ifrs-full:NumberOfSharesIssued
599 Reconciliation of issued capital [Abstract] Abstract auph:ReconciliationofissuedcapitalAbstract
600 Equity, opening balance Concept (Monetary) As Of Credit ifrs-full:Equity
601 Opening adjustment on change in accounting policy (note 3) Concept (Monetary) For Period Credit ifrs-full:IssueOfEquity
602 Exercise of warrants Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
603 Exercise of derivative warrants Concept (Monetary) For Period Credit auph:Increasedecreasethroughexerciseofderivativeliabilitywarrantsequity
604 Exercise of stock options Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
605 Equity, closing balance Concept (Monetary) As Of Credit ifrs-full:Equity
606 2412403 - Disclosure - Share capital - Common shares issued narrative (Details) Network

*

*

 http://www.auriniapharma.com/role/ShareCapitalCommonSharesIssuedNarrativeDetails
607 Disclosure of classes of share capital [table] Table

*

*

 ifrs-full:DisclosureOfClassesOfShareCapitalTable
608 Income Statement Location [Axis] Axis auph:IncomeStatementLocation1Axis
609 Income Statement Location [Domain] Member auph:IncomeStatementLocation1Domain
610 Other income (expense) Member auph:OtherIncomeExpenseMember
611 Classes of ordinary shares [axis] Axis ifrs-full:ClassesOfOrdinarySharesAxis
612 Ordinary shares [member] Member ifrs-full:OrdinarySharesMember
613 Common shares Member auph:CommonsharesMember
614 Warrants Member auph:WarrantsMember
615 Sale of Ordinary Shares, by Type [Axis] Axis auph:SaleofOrdinarySharesbyTypeAxis
616 Sale of Ordinary Shares, by Type [Domain] Member auph:SaleofOrdinarySharesbyTypeDomain
617 Public Offering Member auph:PublicofferingMember
618 Over-allotment offering Member auph:OverallotmentofferingMember
619 Bought Deal Public Offering Member auph:BoughtDealPublicOfferingMember
620 ATM Facilities Member auph:ControlledEquityOfferingMember
621 Disclosure of classes of share capital [line items] LineItems ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
622 Number of shares issued, public offering Concept (Shares) For Period auph:Numberofsharesissuedpublicoffering
623 Share issuance, price per share (in dollars per share) Concept (Share) For Period auph:Shareissuancepricepershare
624 Net proceeds from issuance of common shares Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssueOfOrdinaryShares
625 Private placement, number of shares per Unit Concept (Shares) For Period auph:PrivateplacementnumberofsharesperUnit
626 Warrant exercise period Concept (xbrli:durationItemType) For Period auph:Classofwarrantorrightexerciseperiod
627 Commission rate to allocate share issue costs Concept (Percent) As Of auph:Shareissuecostscommissionpercentage
628 Commission paid to placement agents and filing Concept (Monetary) For Period Debit auph:ShareIssueCostsCommissionAgentFees
629 Bought Deal public offering [Abstract] Abstract auph:BoughtDealpublicofferingAbstract
630 Share issue costs, bought deal units Concept (Monetary) For Period Debit ifrs-full:ShareIssueRelatedCost
631 Commission paid for legal and other professional fees, bought deal units Concept (Monetary) For Period Debit auph:ShareIssueCostsCommissionProfessionalFees
632 ATM Facilities [Abstract] Abstract auph:ATMFacilitiesAbstract
633 Controlled equity offering Concept (Monetary) As Of Credit auph:StockOfferingAmountAuthorized
634 Private placement offerings [Abstract] Abstract auph:PrivateplacementofferingsAbstract
635 Exercise price, price per unit (in dollars per share) Concept (Monetary) For Period Credit auph:Exercisepricesharepurchasewarrant
636 2412404 - Disclosure - Share capital - Disclosure of warrants issued (Details) Network

*

*

 http://www.auriniapharma.com/role/ShareCapitalDisclosureOfWarrantsIssuedDetails
637 Disclosure of classes of share capital [table] Table

*

*

 ifrs-full:DisclosureOfClassesOfShareCapitalTable
638 Sale of Ordinary Shares, by Type [Axis] Axis auph:SaleofOrdinarySharesbyTypeAxis
639 Sale of Ordinary Shares, by Type [Domain] Member auph:SaleofOrdinarySharesbyTypeDomain
640 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
641 Equity [member] Member ifrs-full:EquityMember
642 Warrants Member auph:WarrantsMember
643 Disclosure of classes of share capital [line items] LineItems ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
644 Reconciliation of number of warrants issued [Abstract] Abstract auph:ReconciliationofnumberofwarrantsissuedAbstract
645 Number of warrants issued, opening balance Concept (Shares) As Of auph:Numberofwarrantsissued
646 Warrants exercised Concept (Shares) For Period auph:Numberofwarrantsexercised
647 Number of warrants issued, closing balance Concept (Shares) As Of auph:Numberofwarrantsissued
648 Reconciliation of warrants issued [Abstract] Abstract auph:ReconciliationofwarrantsissuedAbstract
649 Equity, opening balance Concept (Monetary) As Of Credit ifrs-full:Equity
650 Warrants exercised Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
651 Equity, closing balance Concept (Monetary) As Of Credit ifrs-full:Equity
652 2412405 - Disclosure - Share capital - Disclosure of warrants issued narrative (Details) Network

*

*

 http://www.auriniapharma.com/role/ShareCapitalDisclosureOfWarrantsIssuedNarrativeDetails
653 Disclosure of classes of share capital [table] Table

*

*

 ifrs-full:DisclosureOfClassesOfShareCapitalTable
654 Classes of ordinary shares [axis] Axis ifrs-full:ClassesOfOrdinarySharesAxis
655 Ordinary shares [member] Member ifrs-full:OrdinarySharesMember
656 Warrants Member auph:WarrantsMember
657 Sale of Ordinary Shares, by Type [Axis] Axis auph:SaleofOrdinarySharesbyTypeAxis
658 Sale of Ordinary Shares, by Type [Domain] Member auph:SaleofOrdinarySharesbyTypeDomain
659 Disclosure of classes of share capital [line items] LineItems ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
660 Share issuance, price per share (in dollars per share) Concept (Share) For Period auph:Shareissuancepricepershare
661 Warrant exercise period Concept (xbrli:durationItemType) For Period auph:Classofwarrantorrightexerciseperiod
662 Share issue related cost Concept (Monetary) For Period Debit ifrs-full:ShareIssueRelatedCost
663 Fair value per warrant (in dollars per share) Concept (Share) For Period auph:Sharewarrantsfairvalue
664 2412406 - Disclosure - Share capital - Disclosure of outstanding warrants (Details) Network

*

*

 http://www.auriniapharma.com/role/ShareCapitalDisclosureOfOutstandingWarrantsDetails
665 Disclosure of outstanding warrants [Table] Table

*

*

 auph:DisclosureofoutstandingwarrantsTable
666 Currency [Axis] Axis auph:Currency1Axis
667 Currency [Domain] Member auph:Currency1Domain
668 Canada, Dollars Member currency:CAD
669 United States of America, Dollars Member currency:USD
670 Maturity [axis] Axis ifrs-full:MaturityAxis
671 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
672 February 14, 2019 [Member] Member auph:February142019Member
673 December 28, 2021 [Member] Member auph:December282021Member
674 Disclosure of outstanding warrants [Line Items] LineItems auph:DisclosureofoutstandingwarrantsLineItems
675 Number of warrants outstanding Concept (Shares) As Of auph:Numberofwarrantsoutstanding
676 Weighted average excercise price, share warrants outstanding Concept (Monetary) As Of Credit auph:Weightedaverageexercisepricesharewarrantsoutstanding
677 2412407 - Disclosure - Share capital - Disclosure of number and weighted average exercise prices of share options (Details) Network

*

*

 http://www.auriniapharma.com/role/ShareCapitalDisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsDetails
678 Implied Table Table

*

*

 implied:Table
679 Share capital [Abstract] Abstract auph:SharecapitalAbstract
680 Reconciliation of stock options outstanding [Abstract] Abstract auph:ReconciliationofstockoptionsoutstandingAbstract
681 Outstanding – Beginning of year (in shares) Concept (Decimal) As Of ifrs-full:NumberOfOutstandingShareOptions
682 Granted pursuant to Stock Option Plan (in shares) Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
683 Granted pursuant to Section 613(c) of TSX manual (in shares) Concept (Decimal) For Period auph:NumberofshareoptionsgrantedpursuanttoSection613cofTSXmanualinsharebasedpaymentarrangement
684 Exercised (in shares) Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
685 Forfeited (in shares) Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
686 Outstanding – End of year (in shares) Concept (Decimal) As Of ifrs-full:NumberOfOutstandingShareOptions
687 Options exercisable – End of year (in shares) Concept (Decimal) As Of ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
688 Reconciliation of weighted average excercise price, stock options [Abstract] Abstract auph:ReconciliationofweightedaverageexcercisepricestockoptionsAbstract
689 Weighted average exercise price of share options outstanding in share-based payment arrangement, opening balance (in dollars per share) Concept (Monetary) As Of ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement
690 Weighted average exercise price of share options granted in share-based payment arrangement (in dollars per share) Concept (Monetary) For Period ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement
691 Weighted average exercise price of share options granted pursuant to Section 613 (c) of TSX manual in share-based payment arrangement (in dollars per share) Concept (Monetary) For Period Credit auph:WeightedaverageexercisepriceofshareoptionsgrantedpursuanttoSection613cofTSXmanualinsharebasedpaymentarrangement
692 Weighted average exercise price of share options exercised in share-based payment arrangement (in dollars per share) Concept (Monetary) For Period ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement
693 Weighted average exercise price of share options forfeited in share-based payment arrangement (in dollars per share) Concept (Monetary) For Period ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement
694 Weighted average exercise price of share options outstanding in share-based payment arrangement, closing balance (in dollars per share) Concept (Monetary) As Of ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement
695 Weighted average exercise price of share options exercisable in share-based payment arrangement Concept (Monetary) As Of ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement
696 2412408 - Disclosure - Share capital - Disclosure of stock options granted (Details) Network

*

*

 http://www.auriniapharma.com/role/ShareCapitalDisclosureOfStockOptionsGrantedDetails
697 Disclosure of stock options granted [Table] Table

*

*

 auph:DisclosureofstockoptionsgrantedTable
698 Title of Individual [Axis] Axis auph:TitleofIndividualAxis
699 Title of Individual [Domain] Member auph:TitleofIndividualDomain
700 New Director Member auph:NewDirectorMember
701 Employees Member auph:EmployeesMember
702 Chief Executive Officer Member auph:ChiefexecutiveofficerMember
703 Officer Member auph:OfficersMember
704 Directors Member auph:DirectorsMember
705 New Officer Member auph:NewOfficerMember
706 New Employees Member auph:NewEmployeesMember
707 Officers and employees Member auph:OfficersandemployeesMember
708 New officer, new employees and directors Member auph:NewofficernewemployeesanddirectorsMember
709 Vesting [Axis] Axis auph:Vesting1Axis
710 Vesting [Domain] Member auph:Vesting1Domain
711 Tranche one Member auph:TrancheoneMember
712 Tranche two Member auph:TranchetwoMember
713 Disclosure of stock options granted [Line Items] LineItems auph:DisclosureofstockoptionsgrantedLineItems
714 Grant price (in usd per share and cad per share) Concept (Monetary) For Period ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement
715 Number Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
716 Share options granted in share-based payment arrangement, vesting period Concept (xbrli:durationItemType) For Period auph:Shareoptionsgrantedinsharebasedpaymentarrangementvestingperiod
717 Share options granted in share-based payment arrangement, expiration period Concept (xbrli:durationItemType) For Period auph:Shareoptionsgrantedinsharebasedpaymentarrangementexpirationperiod
718 Share options granted in share-based payment arrangement, vesting period percentage Concept (Percent) For Period auph:Shareoptionsgrantedinsharebasedpaymentarrangementvestingperiodpercentage
719 2412409 - Disclosure - Share capital - Stock options and compensation expense narrative (Details) Network

*

*

 http://www.auriniapharma.com/role/ShareCapitalStockOptionsAndCompensationExpenseNarrativeDetails
720 Disclosure of stock options granted [Table] Table

*

*

 auph:DisclosureofstockoptionsgrantedTable
721 Income Statement Location [Axis] Axis auph:IncomeStatementLocation1Axis
722 Income Statement Location [Domain] Member auph:IncomeStatementLocation1Domain
723 Research and Development Expense Member auph:ResearchandDevelopmentExpenseMember
724 Corporate, Administration and Business Development Expense Member auph:CorporateAdministrationandBusinessDevelopmentExpenseMember
725 Currency [Axis] Axis auph:Currency1Axis
726 Currency [Domain] Member auph:Currency1Domain
727 United States of America, Dollars Member currency:USD
728 Canada, Dollars Member currency:CAD
729 Range [axis] Axis ifrs-full:RangeAxis
730 Ranges [member] Member ifrs-full:RangesMember
731 Bottom of range Member ifrs-full:BottomOfRangeMember
732 Top of range Member ifrs-full:TopOfRangeMember
733 Disclosure of stock options granted [Line Items] LineItems auph:DisclosureofstockoptionsgrantedLineItems
734 Expense from share-based payment transactions with employees Concept (Monetary) For Period Debit ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
735 Percent of share options issued in share-based payment arrangement Concept (Percent) For Period auph:Sharebasedpaymentarrangementpercentageofoutstandingstockmaximum
736 Increase (decrease) in percent of share options issued in share-based payment arrangement Concept (Percent) For Period auph:Increasedecreaseinpercentofshareoptionsissuedinsharebasedpaymentarrangement
737 Number of share options issued and outstanding in share-based payment arrangement Concept (Decimal) As Of auph:Numberofshareoptionsissuedandoutstandinginsharebasedpaymentarrangement
738 Number of share options available for issue in share-based payment arrangement Concept (Decimal) For Period auph:Numberofshareoptionsavailableforissueinsharebasedpaymentarrangement
739 Number of share options outstanding in share-based payment arrangement Concept (Decimal) As Of ifrs-full:NumberOfOutstandingShareOptions
740 Percent of share options outstanding in share-based payment arrangement Concept (Percent) As Of auph:Percentofshareoptionsoutstandinginsharebasedpaymentarrangement
741 Number of share options granted pursuant to Section 613(c) of TSX manual in share-based payment arrangement Concept (Decimal) For Period auph:NumberofshareoptionsgrantedpursuanttoSection613cofTSXmanualinsharebasedpaymentarrangement
742 Weighted average exercise price of share options granted pursuant to Section 613 (c) of TSX manual in share-based payment arrangement (in dollars per share) Concept (Monetary) For Period Credit auph:WeightedaverageexercisepriceofshareoptionsgrantedpursuanttoSection613cofTSXmanualinsharebasedpaymentarrangement
743 Information About How Expected Ten Percent Increase in Volatility, Would Increase On Share Options Granted, Expense Amount Concept (Monetary) As Of Debit auph:InformationAboutHowExpectedTenPercentIncreaseinVolatilityWouldIncreaseOnShareOptionsGrantedExpenseAmount
744 Information About How Expected Ten Percent Decrease in Volatility, Would Decrease On Share Options Granted, Expense Amount Concept (Monetary) As Of Credit auph:InformationAboutHowExpectedTenPercentDecreaseinVolatilityWouldDecreaseOnShareOptionsGrantedExpenseAmount
745 Share options pursuant to Section 613(c) of TSX manual in share-based payment arrangement vesting period Concept (xbrli:durationItemType) For Period auph:ShareoptionspursuanttoSection613cofTSXmanualinsharebasedpaymentarrangementvestingperiod
746 Share options pursuant to Section 613(c) of TSX manual in share-based payment arrangement expiration period Concept (xbrli:durationItemType) For Period auph:ShareoptionspursuanttoSection613cofTSXmanualinsharebasedpaymentarrangementexpirationperiod
747 Number of share options exercised pursuant to Section 613(c) of TSX manual in share-based payment arrangement Concept (Shares) For Period auph:NumberofshareoptionsexercisedpursuanttoSection613cofTSXmanualinsharebasedpaymentarrangement
748 Shares issued pursuant to Section 613(c) of TSX manual in share-based payment arrangement outstanding Concept (Shares) As Of auph:SharesissuedpursuanttoSection613cofTSXmanualinsharebasedpaymentarrangementoutstanding
749 2412410 - Disclosure - Share capital - Weighted average assumptions (Details) Network

*

*

 http://www.auriniapharma.com/role/ShareCapitalWeightedAverageAssumptionsDetails
750 Implied Table Table

*

*

 implied:Table
751 Share capital [Abstract] Abstract auph:SharecapitalAbstract
752 Annualized volatility Concept (Percent) For Period ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
753 Risk-free interest rate Concept (Percent) For Period ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
754 Life of options in years Concept (Decimal) For Period ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
755 Estimated forfeiture rate, share options granted Concept (Percent) For Period auph:Estimatedforfeiturerateshareoptionsgranted
756 Expected dividend as percentage, share options granted Concept (Percent) For Period ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
757 Exercise price, share options granted Concept (Monetary) For Period ifrs-full:ExercisePriceShareOptionsGranted
758 Market price on date of grant, share options granted Concept (Share) For Period auph:Marketpriceondateofgrantshareoptionsgranted
759 Share options granted, fair value Concept (Share) For Period auph:Shareoptionsgrantedfairvalue
760 2412411 - Disclosure - Share capital - Disclosure of stock options outstanding (Details) Network

*

*

 http://www.auriniapharma.com/role/ShareCapitalDisclosureOfStockOptionsOutstandingDetails
761 Disclosure of number and weighted average remaining contractual life of outstanding share options [table] Table

*

*

 ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable
762 Currency [Axis] Axis auph:Currency1Axis
763 Currency [Domain] Member auph:Currency1Domain
764 Canada, Dollars Member currency:CAD
765 Range [axis] Axis ifrs-full:RangeAxis
766 Ranges [member] Member ifrs-full:RangesMember
767 Top of range Member ifrs-full:TopOfRangeMember
768 Bottom of range Member ifrs-full:BottomOfRangeMember
769 Ranges of exercise prices for outstanding share options [axis] Axis ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis
770 Ranges of exercise prices for outstanding share options [member] Member ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsMember
771 Exercise price range one [Member] Member auph:ExercisepricerangeoneMember
772 Exercise price range two [Member] Member auph:ExercisepricerangetwoMember
773 Exercise price range three [Member] Member auph:ExercisepricerangethreeMember
774 Exercise price range four [Member] Member auph:ExercisepricerangefourMember
775 Disclosure of number and weighted average remaining contractual life of outstanding share options [line items] LineItems ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems
776 Exercise price of outstanding share options Concept (Monetary) As Of ifrs-full:ExercisePriceOfOutstandingShareOptions
777 Number of stock options outstanding Concept (Decimal) As Of ifrs-full:NumberOfOutstandingShareOptions
778 Weighted average remaining contractual life of outstanding share options (in years) Concept (Decimal) As Of ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions
779 Options exercisable – End of year (in shares) Concept (Decimal) As Of ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
780 2413402 - Disclosure - Nature of expenses - Research and development (Details) Network

*

*

 http://www.auriniapharma.com/role/NatureOfExpensesResearchAndDevelopmentDetails
781 Implied Table Table

*

*

 implied:Table
782 Expenses by nature [abstract] Abstract ifrs-full:ExpenseByNatureAbstract
783 Contract research organizations (CROs) and other third party clinical trial expenses Concept (Monetary) For Period Debit auph:Researchanddevelopmentexpensestudycontractsconsultingandotheroutsideservices
784 Drug supply and distribution Concept (Monetary) For Period Debit auph:Researchanddevelopmentexpensedrugsupplyanddistribution
785 Salaries, incentive pay and employee benefits Concept (Monetary) For Period Debit auph:Researchanddevelopmentexpensewagesandemployeebenefits
786 Stock compensation expense Concept (Monetary) For Period Debit auph:Researchanddevelopmentexpensetravelinsurancepatentannuityfeesandlegalfeesandother
787 Travel, insurance, patent annuity fees, legal fees and other Concept (Monetary) For Period Debit auph:Researchanddevelopmentexpensestockcompensationexpense
788 Research and development expense Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
789 2413403 - Disclosure - Nature of expenses - Corporate, administration and business development (Details) Network

*

*

 http://www.auriniapharma.com/role/NatureOfExpensesCorporateAdministrationAndBusinessDevelopmentDetails
790 Implied Table Table

*

*

 implied:Table
791 Expenses by nature [abstract] Abstract ifrs-full:ExpenseByNatureAbstract
792 Salaries, incentive pay, director fees and employee benefits Concept (Monetary) For Period Debit auph:Corporateadministrationandbusinessdevelopmentwagesbenefitsandseverancecosts
793 Stock compensation expense Concept (Monetary) For Period Debit ifrs-full:ProfessionalFeesExpense
794 Professional and consulting fees Concept (Monetary) For Period Debit auph:Corporateadministrationandbusinessdevelopmentstockcompensationexpense
795 Rent, insurance, information technology and other public company operating costs Concept (Monetary) For Period Debit auph:Corporateadministrationandbusinessdevelopmentrentinsuranceinformationtechnologyandotherpublicoperatingcosts
796 Travel, tradeshows and sponsorships Concept (Monetary) For Period Debit auph:Corporateadministrationandbusinessdevelopmenttraveltradeshowsandsponsorships
797 Corporate, administration and business development Concept (Monetary) For Period Debit ifrs-full:GeneralAndAdministrativeExpense
798 2414402 - Disclosure - Other expenses (income) - (Details) Network

*

*

 http://www.auriniapharma.com/role/OtherExpensesIncomeDetails
799 Implied Table Table

*

*

 implied:Table
800 Other Expenses (Income) [Abstract] Abstract auph:OtherExpensesIncomeAbstract
801 Finance Income [Abstract] Abstract auph:FinanceIncomeAbstract
802 Interest income Concept (Monetary) For Period Credit ifrs-full:RevenueFromInterest
803 Loss on sale of short term investments Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnDisposalsOfInvestments
804 Interest income Concept (Monetary) For Period Credit ifrs-full:FinanceIncome
805 Other - Other Expense (Income) [Abstract] Abstract auph:OtherOtherExpenseIncomeAbstract
806 Revaluation adjustment on contingent consideration (note 10) Concept (Monetary) For Period Debit auph:Revaluationofcontingentconsiderations
807 Foreign exchange loss (gain) and other Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
808 Loss on disposal of equipment Concept (Monetary) For Period Credit ifrs-full:GainsOnDisposalsOfPropertyPlantAndEquipment
809 Other expense (income), classified under other expense (income) Concept (Monetary) For Period Debit auph:Otherexpenseincomeclassifiedunderotherexpenseincome
810 Other expense (income) (note 13) Concept (Monetary) For Period Credit ifrs-full:OtherOperatingIncomeExpense
811 2415402 - Disclosure - Income taxes - Disclosure of income taxes (Details) Network

*

*

 http://www.auriniapharma.com/role/IncomeTaxesDisclosureOfIncomeTaxesDetails
812 Disclosure of temporary difference, unused tax losses and unused tax credits [table] Table

*

*

 ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable
813 Tax Period [Axis] Axis auph:TaxperiodAxis
814 Tax Period [Domain] Member auph:TaxperiodDomain
815 Tax Year 2029 [Member] Member auph:Taxyear2029Member
816 Tax Year 2030 [Member] Member auph:Taxyear2030Member
817 Tax Year 2031 [Member] Member auph:Taxyear2031Member
818 Tax Year 2032 [Member] Member auph:Taxyear2032Member
819 Tax Year 2033 [Member] Member auph:Taxyear2033Member
820 Tax Year 2034 [Member] Member auph:Taxyear2034Member
821 Tax Year 2035 [Member] Member auph:Taxyear2035Member
822 Tax Year 2036 [Member] Member auph:Taxyear2036Member
823 Tax Year 2037 [Member] Member auph:Taxyear2037Member
824 Tax Year 2038 [Member] Member auph:Taxyear2038Member
825 Disclosure of temporary difference, unused tax losses and unused tax credits [line items] LineItems ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems
826 Non-capital losses carried forward Concept (Monetary) As Of Credit auph:OperatingLossCarryforward
827 Federal investment tax credits Concept (Monetary) As Of Credit auph:TaxCreditCarryforwardAmount1
828 SRED amounts Concept (Monetary) As Of Credit auph:Scientificresearchandexperimentaldevelopmentexpenditurescarryforward
829 2415403 - Disclosure - Income taxes - Disclosure of deferred tax assets (liabilities) (Details) Network

*

*

 http://www.auriniapharma.com/role/IncomeTaxesDisclosureOfDeferredTaxAssetsLiabilitiesDetails
830 Disclosure of temporary difference, unused tax losses and unused tax credits [table] Table

*

*

 ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable
831 Temporary difference, unused tax losses and unused tax credits [axis] Axis ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis
832 Temporary difference, unused tax losses and unused tax credits [member] Member ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember
833 Loss carry-forwards Member ifrs-full:UnusedTaxLossesMember
834 Deferred revenue and contingent consideration Member auph:DeferredrevenueandcontingentconsiderationMember
835 Share issue costs Member auph:ShareissuecostsMember
836 Property and equipment Member ifrs-full:OtherPropertyPlantAndEquipmentMember
837 Intangible assets Member ifrs-full:OtherIntangibleAssetsMember
838 SRED Member auph:ScientificResearchandDevelopmentExpendituresMember
839 Other Member ifrs-full:OtherTemporaryDifferencesMember
840 Disclosure of temporary difference, unused tax losses and unused tax credits [line items] LineItems ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems
841 Deferred tax assets (liabilities) Abstract ifrs-full:DeferredTaxAssetsAndLiabilitiesAbstract
842 Deferred tax assets (liabilities) Concept (Monetary) As Of ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
843 Deferred tax assets Concept (Monetary) As Of Debit ifrs-full:DeferredTaxAssets
844 Potential tax assets not recognized Concept (Monetary) As Of Debit auph:DeferredTaxAssetsPotentialTaxAssetsNotRecognized
845 Net deferred tax assets Concept (Monetary) As Of Debit ifrs-full:NetDeferredTaxAssets
846 2415404 - Disclosure - Income taxes - Disclosure of income tax recovery (Details) Network

*

*

 http://www.auriniapharma.com/role/IncomeTaxesDisclosureOfIncomeTaxRecoveryDetails
847 Disclosure of temporary difference, unused tax losses and unused tax credits [table] Table

*

*

 ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable
848 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
849 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
850 Canada Member country:CA
851 Disclosure of temporary difference, unused tax losses and unused tax credits [line items] LineItems ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems
852 Statutory tax rate Concept (Percent) For Period ifrs-full:ApplicableTaxRate
853 2416402 - Disclosure - Net loss per common share - Earnings per share computation (Details) Network

*

*

 http://www.auriniapharma.com/role/NetLossPerCommonShareEarningsPerShareComputationDetails
854 Implied Table Table

*

*

 implied:Table
855 Net loss per common share [Abstract] Abstract auph:NetlosspercommonshareAbstract
856 Net loss for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
857 Weighted average number of ordinary shares outstanding Concept (Shares) For Period ifrs-full:WeightedAverageShares
858 Net loss per common share (expressed in $ per share) Concept (Share) For Period ifrs-full:BasicAndDilutedEarningsLossPerShare
859 2416403 - Disclosure - Net loss per common share - Anti-dilutive securities (Details) Network

*

*

 http://www.auriniapharma.com/role/NetLossPerCommonShareAntiDilutiveSecuritiesDetails
860 Earnings per share [table] Table

*

*

 ifrs-full:EarningsPerShareTable
861 Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities1 [Axis] Axis auph:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities1Axis
862 Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities1 [Domain] Member auph:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities1Domain
863 Stock options Member auph:EmployeestockoptionMember
864 Warrants (derivative liabilities) Member auph:WarrantsderivativeliabilitiesMember
865 Warrants (equity) Member auph:WarrantsEquityMember
866 Earnings per share [line items] LineItems ifrs-full:EarningsPerShareLineItems
867 Anti-dilutive securities Concept (Shares) For Period auph:AntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareAmount1
868 2417402 - Disclosure - Segment disclosures - revenue based on customer location (Details) Network

*

*

 http://www.auriniapharma.com/role/SegmentDisclosuresRevenueBasedOnCustomerLocationDetails
869 Disclosure of geographical areas [table] Table

*

*

 ifrs-full:DisclosureOfGeographicalAreasTable
870 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
871 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
872 United States Member country:US
873 China Member country:CN
874 Disclosure of geographical areas [line items] LineItems ifrs-full:DisclosureOfGeographicalAreasLineItems
875 Revenue Concept (Monetary) For Period Credit ifrs-full:Revenue
876 2418402 - Disclosure - Supplementary cash flow information - Other Operating Assets and Liabilities (Details) Network

*

*

 http://www.auriniapharma.com/role/SupplementaryCashFlowInformationOtherOperatingAssetsAndLiabilitiesDetails
877 Implied Table Table

*

*

 implied:Table
878 Supplementary Cash Flow Information [Abstract] Abstract auph:SupplementaryCashFlowInformationAbstract
879 Accounts receivable and accrued interest receivable Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
880 Prepaid expenses, deposits and other Concept (Monetary) For Period Debit auph:Adjustmentsforincreasedecreaseinprepaidexpensesanddeposits
881 Adjustments for increase (decrease) in clinical trail deposits Concept (Monetary) For Period Debit auph:Adjustmentsforincreasedecreaseinclinicaltraildeposits
882 Clinical trial contract deposits Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
883 Net change in other operating assets and liabilities (note 17) Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseInWorkingCapital
884 Interest received Concept (Monetary) For Period Debit ifrs-full:InterestReceivedClassifiedAsOperatingActivities
885 2418403 - Disclosure - Supplementary cash flow information - Changes in Investing and Financing Activities (Details) Network

*

*

 http://www.auriniapharma.com/role/SupplementaryCashFlowInformationChangesInInvestingAndFinancingActivitiesDetails
886 Statement of changes in equity [table] Table

*

*

 ifrs-full:StatementOfChangesInEquityTable
887 Investment [Axis] Axis invest:InvestmentAxis
888 Investment [Domain] Member invest:InvestmentDomain
889 Derivative warrants December 28, 2016 Member auph:WarrantsderivativeliabilitiesDecember262016Member
890 Derivative warrants February 14, 2014 Member auph:WarrantsderivativeliabilitiesFebruary142014Member
891 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
892 Equity [member] Member ifrs-full:EquityMember
893 Common shares Member ifrs-full:IssuedCapitalMember
894 Warrants Member auph:WarrantsMember
895 Contributed surplus Member ifrs-full:SharePremiumMember
896 Statement of changes in equity [line items] LineItems ifrs-full:StatementOfChangesInEquityLineItems
897 Change in cash flows from financing and investing [Roll Forward] Abstract auph:ChangeincashflowsfromfinancingandinvestingRollForward
898 Short term investments Abstract auph:CurrentInvestmentsAbstract
899 Beginning balance of short term investments Concept (Monetary) As Of Debit ifrs-full:CurrentInvestments
900 Cash flow - Purchases Concept (Monetary) For Period Credit ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities
901 Cash flow - Disposals Concept (Monetary) For Period Debit ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
902 Non-cash changes - Fair value adjustments Concept (Monetary) For Period Debit auph:FairValueAdjustmentcurrentinvestments
903 Non-cash changes - Opening adjustment on change in accounting policy Concept (Monetary) For Period ifrs-full:IncreaseDecreaseInAccountingEstimate
904 Non-cash changes - Other Concept (Monetary) For Period Debit auph:MiscellaneousOtherAdjustmentsForNonCashItemsCurrentInvestments
905 Ending balance of short term investments Concept (Monetary) As Of Debit ifrs-full:CurrentInvestments
906 Contingent consideration Abstract auph:ContingentConsiderationAbstract
907 Beginning balance contingent consideration Concept (Monetary) As Of Credit auph:Contingentconsideration
908 Contingent consideration milestones paid Concept (Monetary) For Period Credit auph:Paymentofcontingentconsiderationmilestoneachievement
909 Fair value adjustment contingent consideration Concept (Monetary) For Period Debit auph:Fairvalueadjustmentcontingentconsideration
910 Ending balance contingent consideration Concept (Monetary) As Of Credit auph:Contingentconsideration
911 Derivative warrants Abstract auph:DerivativewarrantliabilitiesAbstract
912 Beginning balance derivative warrant liabilities Concept (Monetary) As Of Credit auph:Derivativewarrantliabilities
913 Cash flow - Proceeds from exercise derivative warrants Concept (Monetary) For Period Debit auph:Proceedsfromexerciseofderivativewarrants
914 Non-cash changes - Conversion to Common Shares Concept (Monetary) For Period Debit auph:Warrantsconvertedtocommonsharesderivativewarrantliability
915 Non-cash changes - Fair value adjustments Concept (Monetary) For Period Credit auph:Fairvalueadjustmentsderivativewarrantliability
916 Non-cash changes - Other Concept (Monetary) For Period Debit auph:MiscellaneousOtherAdjustmentsForNonCashItemsDerivativeWarrantLiability
917 Ending balance derivative warrant liabilities Concept (Monetary) As Of Credit auph:Derivativewarrantliabilities
918 Common shares Abstract auph:ReconciliationofissuedcapitalAbstract
919 Beginning balance common shares Concept (Monetary) As Of Credit ifrs-full:IssuedCapital
920 Cash flow - Net proceeds from public offering Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssueOfOrdinaryShares
921 Cash flow - Proceeds from exercise derivative warrants Concept (Monetary) For Period Debit auph:Proceedsfromexerciseofderivativewarrantsissuedcapital
922 Cash flow - Proceeds from exercise warrants Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssuingOtherEquityInstruments
923 Cash flow - Proceeds from exercise options Concept (Monetary) For Period Debit ifrs-full:ProceedsFromExerciseOfOptions
924 Non-cash changes - Conversion to Common Shares Concept (Monetary) For Period Debit auph:Warrantsconvertedtocommonsharesissuedcapital
925 Non-cash changes - Fair value adjustments Concept (Monetary) For Period Credit auph:Fairvalueadjustmentissuedcapital
926 Ending balance common shares Concept (Monetary) As Of Credit ifrs-full:IssuedCapital
927 Warrants Abstract auph:WarrantsAbstract
928 Warrants Concept (Monetary) As Of Credit auph:Warrants
929 Non-cash changes - Conversion to Common Shares Concept (Monetary) For Period Debit auph:Warrantsconvertedtocommonshares
930 Warrants Concept (Monetary) As Of Credit auph:Warrants
931 Capital reserve [Abstract] Abstract auph:CapitalreserveAbstract
932 Beginning balance capital reserve Concept (Monetary) As Of Credit ifrs-full:CapitalReserve
933 Non-cash changes - Conversion to Common Shares Concept (Monetary) For Period Debit auph:Warrantsconvertedtocommonsharescapitalreserve
934 Non-cash changes - Stock Based Compensation Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForSharebasedPayments
935 Ending balance capital reserve Concept (Monetary) As Of Credit ifrs-full:CapitalReserve
936 2419402 - Disclosure - Related parties - Compensation awarded to key management (Details) Network

*

*

 http://www.auriniapharma.com/role/RelatedPartiesCompensationAwardedToKeyManagementDetails
937 Implied Table Table

*

*

 implied:Table
938 Related parties [Abstract] Abstract auph:RelatedpartiesAbstract
939 Salaries and short-term employee benefits Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
940 Bonuses accrued or paid Concept (Monetary) For Period Debit auph:Keymanagementpersonnelcompensationbonusaccruedorpaid
941 Severance costs Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
942 Director fees Concept (Monetary) For Period Debit ifrs-full:DirectorsRemunerationExpense
943 Stock-based compensation Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
944 Key management personnel compensation Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensation
945 2419403 - Disclosure - Related parties - Narrative (Details) Network

*

*

 http://www.auriniapharma.com/role/RelatedPartiesNarrativeDetails
946 Disclosure of transactions between related parties [table] Table

*

*

 ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesTable
947 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
948 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
949 Executive officers and directors [Member] Member auph:ExecutiveofficersanddirectorsMember
950 Key management personnel of entity or parent [member] Member ifrs-full:KeyManagementPersonnelOfEntityOrParentMember
951 Joint ventures where entity is venturer Member ifrs-full:JointVenturesWhereEntityIsVenturerMember
952 Disclosure of transactions between related parties [line items] LineItems ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesLineItems
953 Key management personnel compensation Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensation
954 Legal fees Concept (Monetary) For Period Debit ifrs-full:ServicesReceivedRelatedPartyTransactions
955 Contingent consideration payable Concept (Monetary) For Period ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions
956 2420402 - Disclosure - Commitments and contingencies - (Details) Network

*

*

 http://www.auriniapharma.com/role/CommitmentsAndContingenciesDetails
957 Disclosure of Commitments [Table] Table

*

*

 auph:DisclosureofCommitmentsTable
958 Range [axis] Axis ifrs-full:RangeAxis
959 Ranges [member] Member ifrs-full:RangesMember
960 Bottom of range Member ifrs-full:BottomOfRangeMember
961 Top of range Member ifrs-full:TopOfRangeMember
962 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
963 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
964 Entering into significant commitments or contingent liabilities Member ifrs-full:EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember
965 Geographical areas [axis] Axis ifrs-full:GeographicalAreasAxis
966 Geographical areas [member] Member ifrs-full:GeographicalAreasMember
967 Victoria, British Columbia Member auph:VictoriaBritishColumbiaMember
968 Edmonton, Alberta Member auph:EdmontonAlbertaMember
969 Maturity [axis] Axis ifrs-full:MaturityAxis
970 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
971 2019 Member ifrs-full:LaterThanOneYearMember
972 2020 Member ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember
973 2021 Member ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember
974 2022 Member ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember
975 Products and services [axis] Axis ifrs-full:ProductsAndServicesAxis
976 Products and services [member] Member ifrs-full:ProductsAndServicesMember
977 Voclosporin Member auph:VoclosporinMember
978 Disclosure of Commitments [Line Items] LineItems auph:DisclosureofCommitmentsLineItems
979 Area of real estate property (in sqft) Concept (num:areaItemType) For Period auph:LesseeOperatingLeaseAreaofRealEstateProperty
980 Term of contract Concept (xbrli:durationItemType) For Period auph:LesseeOperatingLeaseTermofContract
981 Notice period for cancellation Concept (xbrli:durationItemType) For Period auph:LesseeOperatingLeaseCancellationNoticePeriod
982 Monthly payments Concept (Monetary) For Period Debit ifrs-full:MinimumOperatingLeasePayments
983 Incurred rent expense Concept (Monetary) For Period Debit ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense
984 Minimum lease payments payable under non-cancellable operating lease Concept (Monetary) As Of Credit ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease
985 Purchase obligations Concept (Monetary) As Of Credit auph:PurchaseObligations1
986 Licensee royalty fee Concept (Percent) For Period auph:ContractualCapitalCommitmentsLicenseeRoyaltyFeePercent
987 Royalty fee Concept (Percent) For Period auph:ContractualCapitalCommitmentsRoyaltyFeePercent
988 Disposal of substantially all of product percent of consideration transferred Concept (Percent) For Period auph:ContractualCapitalCommitmentsDisposalofProductConsiderationTransferredPercent
989 2422402 - Disclosure - Financial instruments and fair values (Details) Network

*

*

 http://www.auriniapharma.com/role/FinancialInstrumentsAndFairValuesDetails
990 Disclosure of credit risk exposure [table] Table

*

*

 ifrs-full:DisclosureOfCreditRiskExposureTable
991 Currency [Axis] Axis auph:Currency1Axis
992 Currency [Domain] Member auph:Currency1Domain
993 Canada, Dollars Member currency:CAD
994 Range [axis] Axis ifrs-full:RangeAxis
995 Ranges [member] Member ifrs-full:RangesMember
996 Bottom of range Member ifrs-full:BottomOfRangeMember
997 Top of range Member ifrs-full:TopOfRangeMember
998 Types of risks [axis] Axis ifrs-full:TypesOfRisksAxis
999 Risks [member] Member ifrs-full:TypesOfRisksMember
1000 Liquidity risk [member] Member ifrs-full:LiquidityRiskMember
1001 Interest rate risk Member ifrs-full:InterestRateRiskMember
1002 Currency risk Member ifrs-full:CurrencyRiskMember
1003 Classes of financial assets [axis] Axis ifrs-full:ClassesOfFinancialAssetsAxis
1004 Financial assets, class [member] Member ifrs-full:FinancialAssetsMember
1005 Cash and cash equivalents Member auph:CashandCashEquivalentsMember
1006 Accounts receivable and accrued interest receivable Member ifrs-full:TradeReceivablesMember
1007 Bonds and Treasury Notes Member auph:BondsandTreasuryNotesMember
1008 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
1009 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
1010 Accounts payable and accrued liabilities Member auph:TradeAccountsPayableandOtherLiabilitiesMember
1011 Disclosure of credit risk exposure [line items] LineItems ifrs-full:DisclosureOfCreditRiskExposureLineItems
1012 Cash and cash equivalents instruments, maturity period Concept (xbrli:durationItemType) For Period auph:Cashandcashequivalentsinstrumentsmaturityperiod
1013 Short term investments, maturity period Concept (xbrli:durationItemType) For Period auph:Shortterminvestmentsmaturityperiod
1014 Borrowings, maturity period Concept (xbrli:durationItemType) For Period auph:Borrowingsmaturityperiod
1015 Net exposure Concept (Monetary) As Of ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
1016 Foreign exchange rates [abstract] Abstract ifrs-full:ForeignExchangeRatesAbstract
1017 Exchange rate, CA$ – US$ Concept (Decimal) As Of ifrs-full:ClosingForeignExchangeRate
1018 Ten percent strengthening of CA$ would increase net loss, amount Concept (Monetary) For Period Credit auph:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings
1019 Change in risk variable Concept (Percent) For Period auph:SensitivityAnalysisForTypesForTypesOfTypesMarketRiskReasonablyPossibleChangeInRiskVariablePercent
1020 Ten percent weakening of CA$ would effect income Concept (Monetary) For Period Credit auph:InformationAboutHowExpectedTenPercentWeakeningofDomesticCurrencyWouldEffectIncomeLossAmount
1021 2423401 - Disclosure - Subsequent event (Details) Network

*

*

 http://www.auriniapharma.com/role/SubsequentEventDetails
1022 Disclosure of non-adjusting events after reporting period [table] Table

*

*

 ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodTable
1023 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
1024 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
1025 Major ordinary share transactions Member ifrs-full:MajorOrdinaryShareTransactionsMember
1026 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
1027 Equity [member] Member ifrs-full:EquityMember
1028 Warrants Member auph:WarrantsMember
1029 Classes of ordinary shares [axis] Axis ifrs-full:ClassesOfOrdinarySharesAxis
1030 Ordinary shares [member] Member ifrs-full:OrdinarySharesMember
1031 Common shares Member auph:CommonsharesMember
1032 Sale of Ordinary Shares, by Type [Axis] Axis auph:SaleofOrdinarySharesbyTypeAxis
1033 Sale of Ordinary Shares, by Type [Domain] Member auph:SaleofOrdinarySharesbyTypeDomain
1034 ATM Facility Member auph:AttheMarketFacilityMember
1035 Private Placement Offering Feb 14 2014 Member auph:PrivatePlacementOfferingFeb142014Member
1036 Disclosure of non-adjusting events after reporting period [line items] LineItems ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems
1037 Net proceeds from issuance of common shares Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssueOfOrdinaryShares
1038 Number of shares issued Concept (Shares) For Period auph:Numberofsharesissuedcontrolledequityoffering
1039 Weighted average share price Concept (Monetary) For Period ifrs-full:WeightedAverageSharePrice
1040 Share issue related cost Concept (Monetary) For Period Debit ifrs-full:ShareIssueRelatedCost
1041 Proceeds from issuing shares Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssuingShares
1042 Commission rate Concept (Percent) As Of auph:Descriptionofcommissionratetoallocateshareissuecostscontrolledequityofferings
1043 Granted pursuant to Stock Option Plan (in shares) Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
1044 Commission paid to agent, controlled equity offerings Concept (Monetary) For Period Debit auph:Commissionpaidtoagentcontrolledequityofferings
1045 Commission paid for professional and filing fees Concept (Monetary) For Period Debit auph:Commissionpaidforprofessionalandfilingfeescontrolledequityofferings
1046 Issued pursuant to exercise of stock options (in shares) Concept (Shares) For Period auph:Numberofsharesissuedoptionsexercised
1047 Number of share options exercised in share-based payment arrangement Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
1048 Exercise price, share options granted Concept (Monetary) For Period ifrs-full:ExercisePriceShareOptionsGranted
1049 Number of warrants exercised Concept (Shares) For Period auph:Numberofwarrantsexercised
1050 Exercise price of warrants exercised Concept (Monetary) For Period Debit auph:Exercisepriceshareoptionsexercised
1051 Issued pursuant to exercise of warrants (in shares) Concept (Shares) For Period auph:Numberofsharesissuedwarrantsexercised
1052 Number of shares issued from cashless warrants exercised (in shares) Concept (Shares) For Period auph:Numberofsharesissuedwarrantsexercisedcashless
1053 Number of cashless warrants exercised (in shares) Concept (Shares) For Period auph:Numberofwarrantsexercisedcashless
1054 Transfer of derivative warrant liability to equity Concept (Monetary) For Period Debit auph:Transferbetweenfinancialliabilitiesandequityattributabletoexerciseofwarrants
1055 Derivative warrant liability adjustment Concept (Monetary) For Period Credit auph:Gainlossonfairvalueadjustmentofderivativewarrantliabilities
1056 Derivative warrant liabilities Concept (Monetary) As Of Credit ifrs-full:DerivativeFinancialLiabilities

*

*